Tissue engineered constructs to model early and late-stage atherosclerosis by Mallone, Anna
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Tissue engineered constructs to model early and late-stage atherosclerosis
Mallone, Anna
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-160050
Dissertation
Published Version
Originally published at:
Mallone, Anna. Tissue engineered constructs to model early and late-stage atherosclerosis. 2018, Uni-
versity of Zurich, Faculty of Science.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
TISSUE ENGINEERED CONSTRUCTS  
TO MODEL EARLY AND LATE-STAGE 
ATHEROSCLEROSIS 
 
 
 
 
 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF SCIENCE 
OF THE UNIVERSITY OF ZURICH 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
 
 
 
 
 
Anna Mallone 
January 2018 
 
 
 
 
 
 
 
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
Abstract  
 
 
 
Atherosclerosis is a chronic inflammatory vascular pathology characterized by the 
formation of fatty streaks, also known as plaques, causing vessel stenosis and impairing 
the physiological blood flow. Atherosclerotic plaques are cholesterol-induced 
inflammatory niches accumulating in the vascular sub-endothelial space. Cellular and 
extracellular composition of human plaques is maneuvered by local inflammation that 
leads to alterations in the original vascular microenvironment. Up to date, no optimal 
in vivo or in vitro model mimicking the human disease pathophysiology does exist. In 
the present dissertation, I introduce two new tissue engineered human cell-based in 
vitro models for the investigation of atherosclerosis pathomechanisms both in the early 
and late-stages of disease development. Chapter 1 introduces the key concepts of tissue 
engineering and atherosclerosis disease onset and progression, and provides an 
excursus on current models used to mimic different disease stages. Chapter 2 details 
the design, the fabrication and the computational fluid dynamics investigation of a new 
fluidic chamber for the simultaneous multiple production of miniaturized tissue 
engineered vessels. Furthermore, in this chapter, a new in vitro human-cell based model 
mimicking early disease stages is presented. Chapter 3 describes the invention of the 
first late-stage in vitro disease model of atherosclerosis which is based on the 
production of spheroid, plaque-like cellular aggregates. Finally, Chapter 4 summarizes 
the models presented in this dissertation and examines advantages and possible use of 
such models for future research. Collectively these studies deepen our knowledge and 
understanding of atherosclerosis modeling and disease aetiopathogenesis. 
 
 
 
 
 
 
iv 
Zusammenfassung 
 
 
 
Atherosklerose ist eine chronisch entzündliche Erkrankung der Blutgefäße. Sie ist 
gekennzeichnet durch die Bildung von Fetteinlagerungen, auch bekannt als Plaques, 
welche wiederum eine Gefäßstenose und eine Reduzierung des physiologischen 
Blutflusses verursachen. Atherosklerotische Plaques sind cholesterininduzierte 
Entzündungsnischen, die sich im subendothelialen Raum der Blutgefäße ansammeln. 
Die zelluläre und extrazelluläre Zusammensetzung der Plaques wird durch die lokale 
Entzündung und die daraus resultierenden Veränderungen in der ursprünglichen 
Gefäßumgebung bestimmt. Bislang existieren keine in vivo oder in vitro Modelle, die 
die zugrunde liegende Pathophysiologie optimal nachbilden können. In dieser 
Dissertation stelle ich zwei neue auf Tissue-Engineering und humanen Zellen 
basierende in vitro Modelle vor, die der Erforschung des Pathomechanismus der 
Atherosklerose sowohl im Früh- als auch im Endstadium dienen. Kapitel 1 gibt 
Einblicke in die Grundlagen des Tissue-Engineerings sowie Entstehung und Verlauf 
der Atherosklerose. Des Weiteren werden aktuelle Modelle zur Simulation der 
verschiedenen Krankheitsstadien beschrieben. Kapitel 2 behandelt das detaillierte 
Design, die Herstellung und die computerbasierte Analyse der Strömungsdynamik 
einer neuartigen „Fluidic Chamber“, die der gleichzeitigen Produktion multipler 
Miniatur-Blutgefäße dient. Darüber hinaus wird ein neues in vitro Modell basierend 
auf humanen Zellen erläutert, welches das Frühstadium der Krankheit nachbildet. 
Kapitel 3 umschreibt die Erfindung des ersten in vitro Krankheitsmodells, das das 
Endstadium der Atherosklerose simuliert und auf der Bildung sphärischer, Plaque-
ähnlicher Zellaggregate beruht. Kapitel 4 resümiert alle hier präsentierten Modelle und 
 
 
 
v 
benennt Vorteile und möglichen Nutzen dieser Modelle für die zukünftige Forschung. 
Insgesamt vertiefen die hier dargestellten Studien unser Grundverständnis für die 
Modellierung und für die Ätiopathogenese der Atherosklerose. 
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Introduction 
 
The work for this dissertation is dualistic. First, I have designed and fabricated a fluidic 
chamber hosting tissue engineered small-caliber vessels. With the aim of modeling the 
conditions of the early stages of atherosclerosis disease, I setup a specific culturing 
environment with a focus on key athero-causative factors: (i) shear stress on the mini 
vessel walls, (ii) concentration of low-density lipoproteins (LDL) in the culture 
medium and (iii) titer of circulating monocytes. I used the model to investigate time-
dependent infiltration and differentiation of monocytes within the tissue engineered 
vessels and the remodeling of extracellular matrix.  For the second part of the 
dissertation I biofabricated a spheroid model of atherosclerotic plaque. This vascular 
construct resembles for its cellular and extracellular content the late-stage 
atherosclerotic lesion.  I used the artificial plaque to investigate the role of LDL in cell 
population remodeling and viability. This chapter introduces the tools and concepts for 
tissue engineering, gives an introduction to atherosclerosis pathophysiology, and 
finally overviews the in vivo and in vitro models available nowadays to study 
atherosclerotic disease.  
 
1.1 Principles of tissue engineering  
 
Tissue engineering is the science of tissue manufacturing, deeply rooted in the field of 
biotechnology, cellular biology and biochemistry, and combining them for the purpose 
of multicellular system manufacturing. The key steps in tissue engineering are (1) cell 
isolation, expansion, proliferation (ideally cells are isolated from a human tissue), (2) 
 
 
 
 
 
2 
cell seeding and tissue propagation within a biodegradable support matrix, (3) 
extracellular matrix deposition with concomitant scaffold degradation. As last step, 
which justifies the existence of “tissue engineering” is the (4) implantation of the 
bioengineered construct within the host followed by further tissue remodeling 
occurring in vivo[2-4]. These four key points can be fulfilled with different culturing 
techniques and using in vitro bioreactor systems. The final goal is to promote tissue 
formation by reproducing physiological mechanical stimuli provided by pulsatile blood 
flow[5, 6]. The four-step procedure is commonly known as ex vivo (or in vitro) tissue 
engineering strategy. Different tissue engineering approaches have been additionally 
investigated. A different, promising approach is the in vivo (or in situ) strategy which 
is based on the intuitive concept that the most suitable scaffold for a tissue engineered 
(TE) construct is the extra cellular matrix (ECM) of the native tissue itself. Following 
this idea, matrices derived from decellularized tissues[7] as well as biodegradable 
synthetic scaffold matrices have been studied for direct implantation within the patient. 
This strategy allows spontaneous transmigration and active recruitment of circulating 
endogenous cells to achieve an in vivo scaffold repopulation [8, 9]. Nowadays, the in 
vitro production tissue engineered constructs through conditioned systems 
(bioreactors), is the most widespread methodology aiming at stimulating adequate 
cellular proliferation and ECM deposition via a combination of both biochemical and 
bio-mechanical stimuli.  
In cardiovascular tissue engineering, bio-mechanical stimuli are introduced 
using   pulsating medium flow. Flow pulsatility has been reported to be beneficial for 
myofibroblasts seeded onto the scaffolds, allowing their alignment in the biomaterial 
meshes in the early phases of tissue organization[10, 11]. In 2008 Engelmayr and 
collaborators introduced the flex–stretch–flow bioreactor system for the production of 
tissue engineered heart valves[12], proving the beneficial effects of these mechanical 
constrains on in vitro tissue formation, and providing evidence then it is possible to 
obtain artificial constructs with mechanical properties similar to the native tissues.  
Design and chemical composition of the scaffold matrices employed for tissue 
engineering are critical variables for the success of the biological substitute production 
in both the ex vivo and in vitro approaches. However, other key players are fundamental 
in the process of tissue engineering:  the cell type used for tissue production (in the ex 
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vivo strategy), the ability of scaffold degradation and the quality of extracellular matrix 
deposition[13]. Additionally, in case the bioengineered tissue is designed to be used in 
the clinic, the scaffold material and the culture medium employed for its production 
have to be proven to be xenogen-free[13, 14]. Today’s attempt in developing scaffolds 
fulfilling the aforementioned strict requirements is proceeding in two directions and is 
based on the use of more or less complex polymers from different sources: (i) scaffolds 
from fully synthetical origin or (ii) scaffolds based on biological components. An 
overview of today’s options of biomimetic and biodegradable scaffolds is given in the 
following paragraphs. 
 
1.1.1 Polymeric scaffolds from synthetic sources 
 
Polymeric scaffolds are up to date the mostly used matrices in the cardiovascular field 
and in particular for ex vivo heart valve tissue engineering and vascular engineering. 
The reason of their success is their high durability, high reproducibility and low costs 
as well as their remarkable mechanical strength and predictable physical properties. 
Their physical properties strictly rely on local scaffold stiffness, the main player in 
extracellular matrix production and remodeling. In fact, cells are exposed to different 
local stresses according to the scaffold biomechanical profile. Many studies have 
investigated various fabrication techniques in order to generate novel structures for TE 
applications as polymers assembled with porous designs[15], woven, non-woven and 
electro-spun designs[16]. A huge variety of biodegradable synthetic polymers have 
been synthesized and proposed as suitable TE matrices, such as polyhydroxyalkanoates 
(PHA), polyglycolic acid (PGA), polylactic acid (PLA), polyglactin (PLGA), poly 
(vinyl alcohol), polycaprolactone (PCL) and poly-4-hydroxybutyrate (P4HB)[17], all 
sutable for tissue engineering, being biodegradable and of high malleability.  
 
1.1.1.1 A focus on aliphatic polyesters: PGA, PLA, PLGA and PCL 
 
Despite materials with lower tendency  to  calcification like polytetrafluoroethylene 
(PTFE), polyethyleneterephthalate (PET) and polyurethane (PUR) were initially used 
for the production of bioengineered vessels[18], they show many disadvantages as they 
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are non-degradable, rigid and prone to thrombogenesis. For this reason, they appear 
less suitable for both vascular and valvular graft production when compared to the 
newest polymers available on the market. Among these new flexible and biodegradable 
materials, aliphatic polyester composite structures are considered one of the best 
options for tissue engineering. One of their main features of interest resides in their 
relative resistance to rapid hydrolytic degradation, a remarkable point since artificial 
living systems are cultured in aqueous media[19]. PGA, PCL, PLGA and PLA are all 
synthetic polymers approved for clinical use by Food and Drug Administration (FDA) 
and belong to the aliphatic polyester family. Their erosive degradation ability resides 
in the ester bonds of their polymeric backbone. When used for tissue engineering 
purposes, these compounds undergo macromolecular degradation by random 
hydrolysis and concomitant enzymatic esterase activity[20]. It is necessary to point out 
that monomers resulting from the degradative process of aliphatic polyesters are non-
toxic and can be easily bioresorbed by cells and reintroduced in normal cellular 
metabolic pathways (e.g. oxidized to pyruvic acid). Therefore, these compounds can 
be considered a good choice as starting materials for tissue engineering.  
 
1.1.2 Polymeric scaffolds from biological sources 
 
Biologically derived polymeric scaffolds are either used alone, as plain material, or 
blended with the synthetic polymers described above (e.g. with PLGA)[21, 22]. This 
family of bio-scaffolds includes polysaccharides as alginate, chitin/chitosan, 
hyaluronic acid derivatives and proteins such as collagen, fibrin as well as 
polyhydroxyalkanoates (PHA) and decellularized extracellular matrices[23-26].  In 
addition to the range of options described above, pioneer experiments were conducted 
in order to combine different bio-scaffolds and to create hydrogels of higher 
complexity[27].  
Despite the efforts to introduce these natural polymers in the common TE practice, the 
synthetic materials are still considered a better choice due to their improved strength 
and durability. Moreover, a functionality comparison between natural (or 
decellularized) tissue and natural polymer-based scaffolds still has to be conducted. 
Furthermore, the scaffolds derived from natural polymers still need to be mechanically 
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improved. In particular they show pronounced weakness under stress. Such weakness 
does not allow (for the moment) these biomaterials to be suitable for the culturing 
conditions used in cardiovascular tissue engineering, where a pulsatile flow is applied.  
Although the majority of polymeric scaffolds from biological sources is not 
suitable for cardiovascular tissue engineering, there are some exceptions. One of them 
is Polyhydroxyalkanoates (PHA). PHA are polyester isolated from bacteria cultures 
and can be generated of a desired length (monomer composition) and with a specific 
degradation time by micro tuning the bacterial production pathways. The PHA family 
includes poly-3-hydroxybutyrate (PHB), copolymers of 3-hydroxybutyrate and 3-
hydroxyvalerate (PHBV), poly-4-hydroxybutyrate (P4HB), copolymers of 3-
hydroxybutyrate and 3-hydroxyhexanoate (PHBHHx) and poly-3-hydroxyoctanoate 
(PHO)[28]. PHO, as well as P4HB, have been largely investigated and utilized for 
cardiovascular TE [6, 15, 29]. Unfortunately, an unpleasant drawback of these 
compounds is their slow degradation time which can ultimately impair the tissue 
growth and the expected histological composition of the final bioengineered construct. 
For this reason, PHA polymers are generally combined in low concentration with other 
synthetic polymers to manufacture hybrid scaffolds. The P4HB-coating of PGA 
meshes, indeed, has been reported to be a successful and promising combination of 
biophysical characteristics where the high porosity of PGA is combined with the 
thermoplasticity of P4HB[6, 7]. 
 
1.1.2.1 Polysaccharide-based scaffolds 
 
Polysaccharides are the most accessible, cheap, hemocompatible and non-toxic sources 
of materials for tissue engineering. The monosaccharide units constituting the long 
polysaccharide chains can be tuned by varying the final monosaccharide composition. 
Furthermore, interesting physical properties of the monomers are amplified by the 
polymeric scaffold structure, as different solubility or gelation. Because of their high 
flexibility polysaccharides have been largely used for a variety of purposes in tissue 
engineering, e.g. blood vessels, myocardium, heart valves, bone and other tissue 
engineered constructs but also for encapsulation and delivery of pancreatic islets and 
ovarian follicles [30]. Among the large polysaccharide family, alginate and chitosan 
are today’s best investigated and used materials for TE[27].  Alginate is a 
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biodegradable and bioresorbable polysaccharide derived from brown algae. It is 
composed of repeated glucuronic and mannuronic units that can be easily cross linked 
in solid gel form at room temperature by simply adding bivalent metallic ions such as 
Ca2+ or Mg2+. Its mechanical and physical behavior is highly influenced by the percentage 
of different monomers in the final construct and by their chain length. Some 
disadvantages of alginate have been monitored and reported in literature, i.e. its 
mechanical weakness and poor cell adhesion on the meshes. However, some of these 
obstacles, like the low cell adhesiveness have been already overcome[31, 32]. Chitosan 
is derived from chitin, a biopolymer also found in the exoskeletons of insects. 
Unfortunately, as for  the alginate, its use as scaffold for tissue engineering is limited 
due to low mechanical properties, therefore, studies on  chitosan fibers reinforcement 
have been recently carried out to increase the polysaccharide strength and stiffness in 
proportion to the fiber/scaffold mass ratio but reducing the possibilities to use this 
polymer for cardiovascular tissue engineering[33].  
In the long run, scaffolds as similar as possible to the native ECM will be 
biofabricated. On this regard, hyaluronanic acid (HA) will be largely considered for 
tissue engineering applications. HA is commonly found in the extracellular matrix of 
connective tissues, it is a high molecular weight, non-sulfated glycosaminoglycan 
(GAG) and has been coupled with other biomaterials (e.g. to alginate) to produce 3D-
bioprinted hybrid scaffolds for tissue engineering purposes[34]. The idea of using a 
material which is non-thrombogenic, well structured, retaining space filling 
physiological properties is remarkable. In addition, mechanic weaknesses have been 
recently overcome by co-polymerization with other relevant synthetic or natural 
polymers[35]. Interestingly, the small disaccharides derived from HA degradation, are 
released in concomitance to tissue formation, were shown to promote extracellular 
matrix production[36], an advantageous point for the improvement of mechanical 
features of HA and for a potential use in cardiovascular tissue engineering. 
 
1.1.2.2 Protein-based scaffolds 
 
Protein-based scaffolds can artificially reproduce several features of ECM and also 
retain the potential to positively influence growth and native organization of cells 
during tissue formation. Collagen (mainly collagen type I) and fibrin are today’s best 
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options among protein based matrices for TE because of their bioresorbable properties 
and malleability. Thanks to its fibrillar nature, collagen can be shaped according to 
structural tissue requirements either into sponges, sheets, gels or fiber-based 
scaffolds[37-40]. Scaffolds from this polypeptide are characterized by long 
degradation times and by scarce availability, since human collagen is difficult to obtain 
from human tissue explants. Fibrin is composed of fibrinogen  units and, like collagen, 
can be derived directly from human tissue samples, with all the advantages of 
autologous scaffold production[41]. Fibrin is a malleable polymer possibly modified 
in hydrogels, beads and glue[42]. Degradation of these scaffolds can be diminished or 
increased by varying the amount of fibrinolysis blocking agents in the culturing 
medium, such as the serin protease inhibitor aprotinin[24]. The high softness, the 
tendency to shrinkage and the rapid degradation are still major issues to overcome. 
Great efforts have been done in this direction, e.g. the use of poly(l-lysine) chemical 
treatment of the scaffold in order to improve the mechanical properties. However, still 
more has to be done in view of the use of this interesting biomaterial for bioengineering 
purposes. 
1.1.2.3 Scaffolds derived from decellularized tissues 
 
The excursion on the different scaffolds for in vitro engineering of heart valves ends at 
decellularized tissue-derived matrices. The goal of a good bioresorbable scaffold, 
besides providing a stable growing substrate for the cells, is to encompass as much as 
possible the features of the tissue-specific ECM[43]. The use of native tissue-derived 
templates composed of structured ECM proteins directly organized in their native 
architecture is inevitably attractive. Additionally, the idea that hemodynamic and  
biomechanical properties are already similar or identical to those of their native 
counterpart is even more interesting for tissue engineering applications[3]. When 
considering tissue-derived ECM scaffolds for TE, one of the main issue is the tissue 
source. The concerns on using ECM derived from either xenogeneic or allogeneic 
donors are related to the possible triggering of immune reactions. An additional issue 
of native ECM is the high risk of disease transmissions due to the use of former living 
substrates, as Prion diseases and retroviruses. A strategy for safe retrieval and use of 
tissue-specific ECM in tissue engineering has been recently optimized and is based on 
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decellularization processes. The use of this technique has been proven to decrease the 
immunological response without limiting the cellular remodeling capacity and 
positively impacting the long-term durability of the artificial constructs[7]. Homografts 
or xenografts are today’s most used choices as scaffold matrices. In this regard, Weber 
et al. investigated the repopulation capacity of decellularized tissue-engineered heart 
valves in a non-human primate model conducting an 8 weeks follow-up study[7]. They 
showed for the first time a remarkable and rapid cellular repopulation of the 
decellularized constructs and high remodeling capacities, proving how such an 
approach would be feasible for a translation into the clinical practice. The different 
decellularization protocols described in literature are proven to preserve the resident 
ECM with its mechanical characteristics[44] and to remove all cells entrapped in the 
tight, low porosity and branched protein network[45]. The native ECM is characterized 
by a complex protein structure. In order to preserve matrix integrity and functionality 
and to maintain the construct biosafety protease inhibitors are use in concomitance with 
a nucleic acid digestion step[46]. 
 
1.1.4 Cells for cardiovascular tissue engineering  
 
Beside the choice of a proper biomaterial, an additional variable has to be considered 
to ultimate the production a TE construct: the cell type(s) seeded within the scaffolds. 
Moreover, it has to be considered whether the construct will have a single cell type 
composition or will be produced in co-culture (e.g. myofibroblasts and endothelial 
cells). The cell types used for manufacturing a TE tissue should be of easy isolation 
from the donor via a non-invasive procedure or derived from surgical waste material. 
Importantly, the cells should be of autologous origin, non-immunogenic and with 
pronounced plasticity.  
Despite the difficulties in finding the cell type encompassing those ideal 
characteristics, many improvements have been done in research on the best 
candidates[47], including the attempt to understand the real requirements of scaffold 
seeding. Recent discoveries proved that circulating blood cells or cells from adjacent 
tissues can easily migrate and grow within the scaffold in vivo[48]. However, 
considering the case of the scaffold implantation alone, further challenges have to be 
approached such as the issue of immune response activation by foreign material or by 
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danger-associated molecular pattern molecules (DAMPs) that are released into 
extracellular space by necrotic cells in the growing tissue[49]. A wide panel of cell 
types have been investigated for TE as cells from vascular origin, adipose tissue, 
umbilical cord, chorionic villi, amniotic fluid or cells directly differentiated from 
patient’s induced pluripotent stem cells (iPSCs). Herein, we focus on the mostly used 
and most promising sources for cardiovascular bioengineering. 
 
1.1.4.1  Cells from vascular origin 
 
Cells harvested from vascular donor tissues (e.g. from peripheral arteries, saphenous 
vein), and combined co-cultures of vascular cell populations are so far the preferred 
approaches for scaffold seeding in experiments with TE vessel[6]. Usually, two main 
cell lines are isolated from donor tissue: myofibroblasts and endothelial cells (ECs). 
The first are responsible for the ECM deposition while the second serve in establishing 
a tightly interconnected and confluent cellular layer in the inner lumen of the TE vessel 
or in the outer layers of the tissue engineered heart valves. The advantage in choosing 
these cell types as a seeding option is that they can be directly harvested from the vessel 
of the recipient patient. However, this implies the use of an invasive procedure. For 
this reason, big efforts have been done in optimizing the isolation and use of the 
circulating endothelial progenitor cells (EPCs). EPCs were identified by Asahara et 
al.[50] in peripheral blood and then proposed as potential cell source for TE. The use 
of these cells allows a milder and non-invasive isolation procedure, making them a 
highly attractive alternative to cells derived from tissue explants. Nevertheless, EPCs 
were employed for in vitro production of tissue engineered heart valves and  their 
potential to provide both interstitial and endothelial function was confirmed[51]. 
1.1.4.2  Cells from the umbilical cord 
 
The human umbilical cord protects and insulates umbilical blood vessels, namely one 
umbilical vein and two umbilical arteries. These vessels are embedded in mucoid 
Wharton’s jelly, a substance of gelatinous consistency derived from extra-embryonic 
mesoderm. The latter is today recognized as a great source of mesenchymal progenitor 
cells (MSC), peculiar adult stem cells retaining the potential of multi lineage 
differentiation and being of particular interest for tissue engineering applications[52]. 
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The umbilical cord is one of the best cell sources for cardiovascular tissue engineering 
since cells with different phenotypes that can be ultimately retrieved from it. Not only 
Wharton’s jelly MSCs can be isolated from umbilical cord but also human umbilical 
vein endothelial cells (HUVECs) and myofibroblasts (HUVMs). Endothelial cells and 
myofibroblasts can also be isolated from both umbilical arteries and EPCs from the 
umbilical cord blood[53, 54]. An additional advantage in comparison to the cells from 
vascular origin derived from adult tissues is the possibility of umbilical cord 
cryopreservation, providing a life-time, expandable cell source.  
1.1.4.3  Stem Cells as promising cell source for tissue engineering 
 
Stem cells are one of today’s most attractive options for cardiovascular tissue 
engineering  mainly because of their high growth rate and potential allowing for fate 
tuning towards different cell types such as endothelial cells, fibroblasts/myofibroblasts 
and smooth muscle cells[55]. Mesenchymal stem cells, for example, share huge 
similarity in phenotype compared to heart valve interstitial cells and were proven to 
stimulate in vivo endothelialization and recruitment of autologous host cells by 
paracrine secretion[56]. Bone marrow and adipose - derived stem cells (BMSCs and 
ADSCs), among the others, have been widely studied as cell source for TE. They are 
currently used for the production of tissue engineered heart valves, showing excellent 
in vivo functionality, native like histological profile and ECM organization[57, 58]. 
However, MSCs have indeed a higher cellular potency compared to BMSCs and 
ADSCs and can be isolated without severe interventions (from e.g. by puncturing the 
iliac crest).  
 One of the most important goals in tissue engineering is the prevention of in vivo 
tissue deterioration and calcification combined with the maintenance of intrinsic 
growth and regeneration capacity. In accordance with this goal, the best cell candidates 
for are embryonic stem cells (ESCs). ESCs are pluripotent, undifferentiated and self-
renewing cells, able to generate all the adult terminally differentiated cell types, with 
the exception of extraembryonic tissues[59]. During the embryonal development, at 
the blastocyst stage, a small number of cells constitutes the inner cell mass (ICM), 
which then further differentiates into the three germ layers (endoderm, mesoderm and 
ectoderm) that are considered to be the developmental starting point for the formation 
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of adult tissues. ESCs are directly derived by the expansion of the ICM in vitro. Despite 
the initial success, the use of ESCs has been associated with with ethical issues and 
with immunogenic and tumorigenic problems[60]. In the last years another interesting 
stem cell source has become available thanks to the studies of Takahashi and 
Yamanaka[61]. They demonstrated the possibility to reprogram terminally 
differentiated cells, as mouse fibroblasts, to a multipotent status, obtaining induced 
pluripotent stem cells (iPSCs). The use of iPSCs for tissue engineering could 
potentially overcome the ethical problems associated with embryonic stem cells due to 
their non-embryonic origin. However, since they retain a gene expression profile close 
to the one of ESCs, they are still associated with high risk of tumor formation. The 
research in this field is now focusing on new transdifferentiation approaches, allowing 
the direct production of the desired cell type (e.g. endothelial cells) from another (e.g. 
skin fibroblasts) by adjusting and fine-tuning the biochemical environment and 
overcoming the harmful iPSC transition step[62].  
 
Figure 1. Tissue engineering in short. Cells are isolated from a tissue donor or from the patient himself (1) and 
expanded via in vitro culture to achieve a proper cell number (2). Upon the choice of a proper scaffold (3) the construct 
is either seeded with a suitable cell type (4) or directly implanted into the patient for in situ tissue engineering. When the 
in vitro strategy is chosen, the construct is cultured in a dynamic environment (5) and finally implanted (6a) or used to 
model the relevant diseases (6b). 
 
 
 
 
 
12 
1.2 Atherosclerosis - causes and consequences 
 
Atherosclerosis is a life threatening vascular pathology characterized by the 
accumulation of a fatty plaque in the vascular sub-endothelial space [63]. 
Atherosclerotic plaque formation is influenced by the synergistic interplay of different 
risk factors such as sex, age, genetic predisposition, high blood pressure and high levels 
of LDL [64, 65]. Being a vascular pathology, atherosclerosis can affect different organs 
of the human body. Stenotic arteries can indeed lead to coronary artery, carotid artery 
and chronic kidney disease and, in the worst case, to acute ischemic events and 
stroke[66].  Given this preamble, it is not surprising that in 2010 atherosclerosis caused 
1 death out of 4 worldwide [67]. The following paragraphs describe the 
pathomechanisms of atherosclerosis and focus on todays’ approaches, including tissue 
engineering strategies, for the treatment of heart failure and acute ischemic events 
caused by the disease. 
 
1.2.1  Development of atherosclerotic plaques 
 
Atherosclerosis is a chronic inflammatory disease but its causative events and 
phatodynamics are still not clearly understood. Atherosclerotic plaque deposition starts 
with a small inflammatory lesion in the sub-endothelium witch is triggered by (i) 
variations shear stress on the vessel lumen[68] and (ii) by local accumulation of LDL 
and its modified versions (e.g. oxidized, acetylated)[69]. It is not yet understood which 
of these triggering events comes first or if both events are equally contributing to 
plaque formation. The process of plaque formation is progressive and reversible [65, 
70]: it can be counteracted by a reduction of the modifiable risk factors mentioned 
above or promoted by their persistence.  
The formation of a well-structured plaque microenvironment results from the 
interplay of cholesterol-rich lipoproteins, endothelial cells, monocytes, macrophages, 
dendritic cells and fibroblasts in a complex matrix milieu [71].  Plaque formation is 
initiated by patrolling monocytes, aggregating in the sub-endothelium. Monocytes and 
other circulating cells from the innate immune system,  are recruited by the endothelial 
cells in the lumen through exposure of adhesion proteins such as  intercellular adhesion 
molecules (ICAMs) and vascular adhesion molecules (VCAMs)[72]. After their 
 
 
 
 
 
13 
recruitment, monocytes extravasate in the sub-endothelium and are exposed to 
accumulating low density lipoproteins. Here, differentiation occurs towards either (i) 
antigen presenting cells (APCs) or (ii) macrophages. The first, beside contributing in 
LDL clearing, exacerbate inflammation by locally recruiting cells from the adaptive 
immune response[73]. The second, upregulate the production of scavenger receptors 
as scavenger receptor class B member 3 (SCARB3 also known as CD36) and scavenger 
receptor A1 (SRA-1)[74]. The scavenger receptors are responsible for clearing cell 
debris, LDL and its modified forms. Ultimately, these events result in the formation of 
the foam cells, a hallmark of the atherosclerotic plaque[75]. The foam cells, not only 
secrete proinflmmatory chemokines and cytokines promoting further recruitment of 
inflammatory cells, but also release macrophage retention factors (such as netrin 1 and 
semaphorin 3E)[76]. These retention factors counteract efferocytosis, namely the 
clearance of apoptotic or necrotic cells, and prevent the emigration towards the 
adventitial lymphatics. The result is a growing niche characterized by a necrotic core, 
foam cells and chronic recruitment of inflammatory cells from both innate and adaptive 
immune response.  
At late developmental plaque stages, the inflammatory niche appears as a well-
structured microenvironment[71]. In particular, smooth muscle cells from the tunica 
media engulf the niche by migrating at its perimeter and differentiating into 
myofibroblasts[70]. The “fibrous cap” is formed. Myofibroblasts actively contribute to 
the niche stability though ECM deposition.  In particular, myofibroblasts release 
collagen and glycosaminoglycans, acting as plaque stabilizers[77, 78]. When the 
necrotic core increases in size, the intra-plaque titer of proteolytic enzymes is 
incremented. Among these enzymes, matrix metalloproteinases (MMPs) seem to be, in 
fact, the main responsible for plaque rupture[79].  
When a rupture occurs, the exposure of tissue factor in the vascular lumen 
triggers the coagulation cascade. Here, depending on the arterial branch where the 
rupture occurred different scenarios are possible: 1) the rupture is healed and re-
endothelialized, increasing vessel stenosis by reducing the lumen diameter  and 
incrementing blood flow turbulence at the plaque site[80]. 2) The rupture causes the 
formation of blood clot that can detach and travel along the vessel and, eventually, 
interrupt the blood flow and the oxygenation of downstream tissues. If the 
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atherosclerotic plaque was originally localized in the branches of coronary arteries, 
scenario number 1 would have led to heart failure, while scenario number 2 to an acute 
ischemic episode. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Atherosclerotic plaque development. From Tabas I. et al. (2010)[1]. Plaque development is 
fostered by a persistent recruitment of monocytes in the intima layer. Here, monocyte phagocyte LDL in its 
native and modified forms, accumulate cholesterol in the cytoplasm and differentiate into lipid-rich cells (foam 
cells). Foam cells contribute to plaque development by releasing inflammatory cytokines and persisting within 
the inflammatory niche.  Moreover, foam cells fail in phagocyting cell debris and promote the formation of a 
necrotic core. The release of enzymatic content from dead cells triggers the thinning of the myofibroblast fibrous 
cap, preamble of plaque rupture. 
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1.2.2  Cardiovascular disease and atherosclerosis 
 
Cardiovascular disease includes a plethora of disorders affecting the cardiovascular 
system comprising, among others, heart failure (HF). Frequently, HF is caused by 
coronary artery atherosclerosis and can lead to acute ischemic episodes (IHD). Due to 
poor or absent post-ischemic reperfusion of the infarcted myocardial areas, a 
significant number of cardiomyocytes undergoes apoptosis and is replaced by fibrous 
scar tissue. The relative unpredictability of acute cardiovascular events, the high 
mortality rate and the absence of a durable post-ischemic treatment, endorse IHD to 
one of the most critical clinical hurdle of this century. The long-term survival of 
patients with heart failure is compromised by a series of complications as the massive 
proliferation of non-contractile fibrotic tissue in the infarcted areas. Additionally, after 
acute ischemic episodes, patients endure life-changing treatments ranging from daily 
medications to surgical interventions as pacemakers, stents, angioplasty or heart 
transplants.  
In this context, regenerative medicine and tissue engineering can be considered 
as innovative and valid treatment alternative. The identification of progenitor cardiac 
cells within the adult human heart [81] encouraged the enthusiasm for cell-based 
regenerative therapies [82-84]. Moreover, the evidence that exogenous cells injected 
in the myocardium could minimally promote the formation of functional contractile 
tissue in the scarred areas provided an important contribution in directing the 
preclinical research towards the investigation of possible new treatments [85]. Despite 
the recent advances of basic research in the field, the detailed architecture of cardiac 
repair response upon ischemia is currently not clear. The presence of progenitor cells 
capable of a local and limited regenerative activity in the adult heart inspired the study 
and development of both (i) cell-based technologies and (ii) strategies for paracrine 
stimulation of the resident cardiac progenitor cells. The next paragraphs will introduce 
and discuss both regenerative approaches.   
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1.2.2.1  Cell-based Regenerative Technologies: from single-cell to 
bioengineered microtissues 
 
Over the past decades preclinical and clinical investigations of cell-based technologies 
for the treatment of the infarcted heart have been carried out.  Different cell-candidates 
were evaluated in vitro and are now under investigation for a possible therapeutic use. 
Examples are autologous in vitro-expanded cardiac progenitor cells (CPCs) and 
autologous adipose or bone marrow derived MSCs [86].  Despite clinical trials based 
on the intra-myocardial injection of single-cell suspensions have been performed with 
mesenchymal autologous cells, the interpretation of the results is controversial and 
roused questions and doubts regarding the power of the technology [87-89]. There is 
currently a consensus regarding the possible reasons for the single-cell suspension 
therapy failure; the negative results are addressed to the scarce survival and retention 
of the cells at the level of the infarcted area [90]. The newest regenerative approaches 
aim at enhancing survival, grafting and retention abilities of the injected cells using 
different methodologies. An example is provided by the cutting-edge bioengineered 
microtissue technology. Microtissues are scaffold-free tissue engineered spheroids 
generated via hanging drop technique. These microstructures a reproducible with 
different cell types like CPCs, bone marrow and adipose tissue derived mesenchymal 
stem cells (Figure 1) [84] and have been tested in a pilot study on infarcted porcine 
models exhibiting promising results [91]. Other methods currently investigated for 
increasing cell retention in the infarcted areas include (i) the combination of single cell 
suspensions with nanoparticles loaded with functional agents [92], (ii) the injection of 
a compact mixture of cells pre-cultured in hydrogels [93] or  (iii) the injection of cell-
free hydrogels functionalized with paracrine mediators [94].  
 
1.2.2.2  Paracrine Stimulation of Resident Progenitor Cells 
The self-regenerative ability of the adult heart is per-se inefficient in stimulating the 
functional replacement of necrotic areas and preventing the formation of fibrous tissue 
after myocardial infarction. Regenerative mechanisms demand tailored triggers that are 
provided by cell-cell communication. It is known that epicardium and endocardium 
share a communication network based on vesicular exchange [95]; cells can indeed 
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exchange information by packing and delivering ribonucleic acids and proteins within 
micro-vesicles known as exosomes (EVs) [96-98]. A branch of recently developed 
regenerative technologies adopted this mechanism of cell-cell communication to 
stimulate and increase the physiological regenerative processes upon injury. The EVs 
vesicular content varies according to environmental clues (i.e. hypoxic conditions or 
acute myocardial infarction) and provides growth factors, anti-apoptotic and 
angiogenic as well as mitogenic signals. In detail, EVs are predominantly enriched in 
microRNAs (miRNA), small non-coding RNA molecules with the function of post-
transcriptional regulators [99]. Cardiomyocyte-specific extracellular factors and 
miRNAs (e.g. miR-1, -133 and -206) are key regulators of cardiac function and are 
released in high concentrations upon heart injury, exerting their regulatory role on the 
surrounding cells [100, 101]. The beneficial and synergic function of specific 
combinations of miRNAs on CPCs has been proven together with the hypothesis that 
miRNA families can be selectively secreted into the extracellular environment via 
exosomes [102, 103]. The recent EV-inspired regenerative technologies focus either 
on the (i) drug-exerted stimulation of cardiac progenitors [104, 105] or on the (ii) in 
situ miRNA targeted delivery [106]. Different studies contributed to the development 
of these technologies, like the in vitro and in vivo investigation of the secretome and 
extracellular vesicular content of mesenchymal stem cells. These studies led to the 
discovery of new cardio-protective molecules [107-110]. In this regard, Timmers et al. 
showed in 2007 the beneficial effects of MSCs-conditioned medium upon injection in 
a pig model of ischemia/reperfusion, reporting a significant reduction in the ischemic 
myocardial area after the treatment [109].  More recently, the secretome of human 
amniotic membrane-derived mesenchymal stromal cells was injected in infarcted rat 
models, leading to a reduction of the ischemic area and ventricular remodeling [107]. 
Although these promising studies are still at the preclinical level, have the potential to 
shorten the distance from clinical trials to a possible therapeutic approach in humans 
[111]. 
1.2.2.3  Considerations on future therapeutic directions  
It is possible to identify few promising future directions for the treatment of HF and 
IHD and other cardiovascular diseases caused by atherosclerosis. One of them is (i) the 
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idea of replacing/combining stem cell-based therapies for the infarcted heart, with an 
intra-myocardial injection of a cardioprotective cocktail. Other intriguing strategies are 
(ii) the use of microtissues as a possible alternative to cell therapy performed with 
single-cell suspensions and (iii) the tissue engineering technology. The first is 
considered a promising cell-delivery system for enhancing cellular engraftment and 
survival in the infarcted myocardium. The second aims at revolutionizing the field of 
cardiac regeneration by promoting the use of decellularized tissues for enhancing in 
situ tissue formation.  Finally, (iv) new drugs for effective treatment of atherosclerosis 
need to be designed to prevent, mitigate or block cardiovascular diseases at their early 
stages. For this purpose, optimal in vitro human cell- based tissue engineered models 
for atherosclerosis need to be introduced in preclinical investigations, for drug design 
and screening. 
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1.3 Modeling atherosclerosis 
 
Since 1856, when R. Virchow described first time the human atherosclerotic plaque, 
there has been the need to develop disease models to gain a better insight on the 
pathomechanisms driving plaque formation[112]. However, the first experiment to 
investigate atherosclerosis development was conducted about 50 years later by the 
Russian Ignatowski, who used rabbits as in vivo model[113]. From then on, different 
in vivo and in vitro models of atherosclerosis were proposed and are still employed in 
today’s research. The following paragraphs summarize the large number of 
atherosclerosis in vivo and in vitro models that can be found in literature. In particular, 
models that allowed key discoveries in the field are presented.  
 
1.3.1  In vivo models  
 
The cellular mechanisms underlying plaque formation and regression have been 
investigated in vivo in both small and large animals, and predominantly in 
hypercholesterolemic mice with knock-out of either Apoe or LDL-receptor [114-116] 
or in non-human primates [117, 118].   
 Historically, rabbits were the first animal model to be employed for 
atherosclerosis studies. Due to their peculiar physiology, rabbits fed with a balanced 
chow are per se not prone to manifest the disease. For this reason, at the time where 
transgenic animals were not available, watanabe hereditary hypercholesterolemic 
rabbits (WHHL) and New Zeland white rabbit (NZW) were employed[119] . WHHL 
are characterized by a mutant LDL receptor and were used by Goldstein and Brown for 
their discoveries concerning the regulation of cholesterol metabolism and for 
understanding the basis of familial hypercholesterolemia. The New Zeland white rabbit 
(NZW) are particularly sensitive to high cholesterol diets and are prone to plaque 
accumulation. More recently different transgenic rabbit models were employed as 
apolipoprotein E II (apoEII) and apolipoprotein B-100 (apoB-100) [120, 121]. The 
main advantages in using rabbit model over mice and rats reside in the fact that rabbits: 
(i) are LDL-animals like humans, meaning low density lipoprotein is the most abundant 
lipoprotein in circulation; mice and rats are high-density lipoprotein (HDL)-animals 
instead. (ii) Rabbit develop cerebral and coronary lesions similar to human, whereas 
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mice do not. Criticisms in using rabbits for atherosclerosis research are linked to two 
main facts: (i) unlike in human plaques, rabbit plaques are solely constituted by foam 
cells and (ii) once rabbits are under high-cholesterol chow (more than 1% cholesterol 
for a long period), their cholesterol concentration is too high in the plasma (exceeding 
2000 mg/dl) and it is not comparable even with the levels measured in 
hypercholesterolemic human patients, and show unusual foamy lesions in the aorta. 
Despite that, rabbits are still used for the investigation of lipid lowering drugs and for 
the development of imaging/diagnostic tools[113]. 
Mice showed to be a great model for investigating the molecular mechanisms 
of disease pathogenesis. Among dozens of mouse models available to study 
atherosclerosis, three of them were crucial for elucidating key atheromechanisms such 
as the role of macrophage colony-stimulating factor (M-CSF), scavenger receptors as 
CD36 and SRA-1, and acyl–coenzyme A cholesterol acyltransferase (ACAT). The 
ApoE -/- model is one of them, showing spontaneous disease onset on normal diet but 
the severity of the disease never reaches plaque rupture[122]. The Ldlr -/- mouse shows 
disease onset only on western-type diet but the lesions have a quite long development 
time [123]. Finally, the Ldlr-/- recombination activation gene (RAG)-/- led to the 
discovery that adaptive immune system is not obligatory required for plaque 
formation[124].  In addition to the limitations in using mouse models in atherosclerosis 
studies that were presented in the previous paragraph, mice also show limited tissue 
availability and generate technical difficulties, due to their small size. Moreover, being 
HDL-animals, wild type mice are relatively atherosclerosis resistant[125]. 
Thanks to shared anatomical similarities in the vascular system to human and 
due to their big size, pigs are considered a very good model to investigate pathological 
hemodynamics and responses of endothelial layer, and for designing and testing 
imaging and diagnostic tools[126]. Being so similar to humans, their lesions often do 
not progress beyond foam cell lesion formation within a reasonable time-frame, 
therefore, strategies to overcome this obstacle have been developed as: (i) selecting for 
natural genetic mutations, (ii) introducing other risk factors for atherosclerosis and, 
most recently, (iii) performing genetic engineering in the Yucatan minipig model[127, 
128]. An outstanding example of genetic engineering in pigs was conducted by Davis 
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et al. in 2014 where the targeted knock-out of the Ldlr gene allowed to obtain 
hypercholesterolemic pigs[129].   
Other large animals employed for the investigation of atherosclerosis 
pathomechanisms are non-human primates. They are optimal models due to their 
outstanding resemblance to humans, spanning from close genetical homology to 
similar omnivorous diet, anatomy, metabolism and aging processes[130]. Studies 
conducted in Rhesus monkeys allowed to prove that plaque can regress upon drastical 
changes in diet[131]. Moreover, investigations performed in cynomolgus macaques 
demonstrated that there are connections linking atherosclerosis gender and social 
behavior[132]. Other studies compared LDL profiles, density and molecular weight 
among non-human primates and between human and non-human primates. The first 
were especially conducted on African green monkey and cynomolgus monkeys and 
concluded that, despite ApoB-100 was the major apoprotein in both species, as it is in 
humans, LDL sub-fractions of cynomolgus had lower densities and larger 
dimensions[133]. This characteristic promotes cynomolgus as one of the best in vivo 
model for human atherosclerosis together with chimpanzee [134]. Beside the 
significant ethical issue raised when such animals are involved in scientific studies, 
non-human primates are expensive to maintain and require long experimental 
periods[130]. 
In conclusion, the “perfect” animal model should be easy to purchase and 
maintain, of relatively small size for optimal handling, have a stable genetic 
background, being able to breed in the lab and develop the disease in reasonable time. 
In addition, the model should be an LDL-animal and share similarities to human in 
plaque composition and location. This implies that such animal should have anatomical 
structures comparable to humans and similar inflammatory response. The above 
requirements, at the moment, are impossible to find in a single animal. In fact, despite 
the stunning contribution to the field, major differences in anatomy, lipoprotein profiles 
and inflammatory mechanisms hampered the translation of results obtained in vivo to 
the human pathophysiology.  
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1.3.2 In vitro models  
 
To overcome the translational gap, human cell-based co-culture in vitro models 
have been established and provided a first glimpse into the mechanisms and initial 
events of plaque deposition in humans [6, 135-137]. In vitro atherosclerosis models 
can be classified in two main categories: indirect and direct models. The first are 
characterized by two or multiple cell types without direct cell-cell contact, that can 
coexist within the same volume, the second are instead characterized by two or multiple 
cell types are in direct cell-cell contact[138]. Within these categories there are two main 
subtypes of model systems: (a) static and (b) dynamic culture systems. 
Examples of relevant in vitro indirect models are conditioned media (CM) 
cultures, bilayer membranes (BiM) and transwell co-culture models (TW). In CM 
cultures, different cell types are grown separately and the culture medium of one 
culture is later transferred onto a different cell substrate to investigate the reactions 
elicited. In the contest of atherosclerosis research such culturing method was used 
mainly to investigate the interactions between smooth muscle cells (SMCs) and 
monocyte/macrophages cultures, to study the process triggering MMPs production in 
plaque SMCs[139, 140]. BiM cultures allow closer proximity between the co-cultured 
cells and were principally employed to investigate interactions between cells from 
triple co-culture, namely SMCs, ECs and monocyte/macrophages[136, 141, 142]. 
Finally, in TW cultures one cell type is grown on the bottom chamber of the culture 
plate while the other is grown separately on top of a porous membrane insert. In 
atherosclerosis research TW systems were used to study cell-cell and cell-substrate 
interactions and, in particular, a majority of the studies carried out have examined 
SMCs proliferation, calcification and apoptosis[143-145].  
Direct models for atherosclerosis encompass different types of cell-cell 
interaction happening at the same time as (i) cell-cell adhesion, (ii) cell-ECM contact 
and (iii) interactions between cell-soluble factors. Examples of such models are and 
gel-based co-cultures (GC) and tissue engineered (TE) constructs (with or without 
supporting scaffold material). GC methods create a biomimetic three-dimensional 
microenvironment in the culture dish, using scaffolds of synthetic and native hydrogels. 
These models are principally used for drug design and screening and aim at maximizing 
 
 
 
 
 
23 
the representativeness and the translation of the results obtained. GC-cultures mimic 
selected in vivo characteristics that influence drug distribution in a standardized and 
reproducible manner[146-148].  TE constructs share the same advantages of GC 
cultures but, in addition aim at avoiding cell co-cultures carried out in a well 
environment and rather provide a surrounding culturing system as similar as possible 
to the native conditions (bioreactor)[138].  TE models are the best available human-
cell based atherosclerosis models. Such models were recently used to either investigate 
early lesion events, as monocyte anchoring at the endothelial surface and extravasating 
in the sub-endothelium[6] or to investigate cellular phenotypes within the biofabricated 
late-stage plaque microenvironment[149]. 
A side category of atherosclerosis in vitro models is based on the „on-a-chip” 
technology. Such models are based on the direct or indirect co-culture of two or more 
cell types in a Polydimethylsiloxane (PDMS)-based microfluidic chamber [150]. 
Despite these models ease the culturing process and facilitate imaging and drug testing 
they lack the complete „set” of vascular features. In fact, they do not retain the classical 
vascular morphology and ECM composition. The atherosclerosis models that will be 
discussed in the next chapters are human cell-based direct co-culture, TE models. The 
following table summarizes the state-of-the-art human cell-based in vitro co-culture 
direct models for atherosclerosis. Advantages and disadvantages are listed. 
 
 
Ref. Cell type Culture 
system 
Focus Comments 
[151] Endothelial cells 
(EC), smooth muscle 
cells (SMC) 
 Static Direct EC regulation of SMC 
proliferation in co-culture 
Advantages: Presence of EC 
Disadvantages: No 3D culture, No LDL in culture 
medium, No monocyte/macrophages/dendritic cells 
[141, 
142] 
EC, SMC, 
monocytes 
 Static Direct Monocyte transmigration Advantages: Presence of EC 
Disadvantages: No 3D culture, scaffold coated with 
gelatin (not physiological –like condition) 
[139] SMC, monocytes and 
lymphocytes 
(PBMCs)  
 Static Direct SMC and monocyte interaction 
causing MMP secretion 
Advantages: - 
Disadvantages: no ECs, presence of a gel scaffold, 
no investigation of lymphocytes function (useless 
for the model). 
[152] EC, SMC, PBMCs Static Direct Investigated role of Heme 
Oxygenase-1 in early 
atherosclerosis 
Advantages: presence of cells from adaptive 
immune response (lymphocytes) 
Disadvantages: No 3D culture, no investigation of 
lymphocytes function (useless for the model). 
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[153] EC, PBMCs Static Direct Reverse transmigration of 
phagocytes across endothelium 
Advantages: presence of cells from adaptive 
immune response (lymphocytes) 
Disadvantages: No SMC, No 3D culture, no 
investigation of lymphocytes function (useless for 
the model), presence of a gel scaffold. 
[140] SMC, Thp-1 
monocytes 
Static Direct or 
Indirect 
(transwell) 
Investigating MMp-1 
production from SMC+ 
monocytes co-culture  
Advantages: - 
Disadvantages: No EC, No 3D culture, No LDL in 
culture medium. 
[154] SMC, Thp-1 
monocytes, PBMCs 
Static Direct or 
Indirect 
(transwell) 
Calcifying phenotype in SMC Advantages: - 
Disadvantages: No EC, No 3D culture, No LDL in 
culture medium, no investigation of lymphocytes 
function (useless for the model). 
[155] SMC, monocytes  Static Direct  SMC apoptosis Advantages: - 
Disadvantages: No EC, No 3D culture, No LDL in 
culture medium. 
[156] SMC, PBMCs Static Direct  SMC proliferation Advantages: - 
Disadvantages: No EC, No 3D culture, No LDL in 
culture medium. 
[144] SMC from different 
vascular origins, 
PBMCs 
Static Direct or 
Indirect 
(transwell) 
Influence of TNFa on SMC 
apoptosis 
Advantages: SMC from different vascular origins 
Disadvantages: No EC, No 3D culture, No LDL in 
culture medium, no investigation of lymphocytes 
function (useless for the model). 
[157] SMC, Thp-1 
monocytes, PBMCs 
Static Direct or 
Indirect 
(transwell) 
Monocyte differentiation and 
apoptosis 
Advantages: - 
Disadvantages: No EC, No 3D culture, No LDL in 
culture medium. 
[137] EC, SMC, 
Monocytes and 
macrophages (Mono-
Mac 6)  
Static Direct  Study early atherosclerosis 
events 
Advantages: presence of Macrophages 
Disadvantages: presence of a gel scaffold 
[158] EC, SMC, 
Granulocytes (PMN)  
Static Direct  Sub endothelial infiltration and 
plaque destabilization 
Advantages: presence of PMN 
Disadvantages: No monocytes, No 3D culture 
[159] EC, SMC from 
different vascular 
origins 
Static Direct  Model healthy and diseased 
blood vessels based 
Advantages: SMC from different vascular origins 
Disadvantages: No monocytes, No 3D culture, no 
LDL in culture medium 
[160] SMC, PBMCs, 
monocyte like cell 
line  U-937 
Static Direct  Inflammatory mediators 
produced by SMC+ monocyte 
co-culture 
Advantages: - 
Disadvantages: No EC, No 3D culture, no LDL in 
culture medium 
[161] EC, SMC, PBMCs Static Direct or 
Indirect 
(transwell) 
Modulation of SMC behavior 
by macrophages 
Advantages: - 
Disadvantages: No 3D culture 
 
Table 1. Direct co-culture in vitro models of atherosclerosis. 
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Chapter 2 
Adapted from: 
Mallone, A., Gericke C., Hosseini V., Vogel V., Hoerstrup, S. P. and Weber, B. (2018) Human cell-based tissue 
engineered small-caliber vessels for investigating early atheroma development, (Manuscript in preparation) 
 
In vitro bioengineering of the early 
lesion 
 
2.1 Introduction and experimental setup 
 
Atherosclerotic plaque development begins with the formation of a small lesion in the 
sub-endothelium where cells from the innate immune response engulf LDL in its native 
and modified state. Among different risk factors it has been shown that high LDL 
cholesterol levels and high blood monocyte count correlate with the progression of 
atherosclerotic lesions[162-165]. In this work we modeled, designed and produced a 
fluidic chamber for the culture of small-caliber tissue engineered vessels to serve as in 
vitro model for early-stage atherosclerosis. In order to biofabricate a construct as 
similar as possible to the coronary artery environment we first produced a tubular, 
biodegradable scaffold matrix of 0.5 mm in diameter. Second, we studied the flow 
within the chamber to investigate the best culturing conditions for the TE constructs. 
For this purpose, we established a computational fluid dynamics (CFD) model 
providing information on velocity, pressure and wall shear stress within the fluidic 
chamber. Third, we set up two different culturing environments to mimic either a (i) 
high-risk, athero-prone condition (190 mg/dl of LDL and 7x105 monocytes/ml) or (ii) 
a low-risk condition (40 mg/dl of LDL and 5x105 monocytes/ml)[166, 167]. We 
sampled the vessel after 3, 4 and 5 weeks of culture. We sorted and investigated the 
sub-endothelial monocyte-derived populations at each time point using flow cytometry 
coupled with t-distributed stochastic neighbor embedding data analysis (t-SNE)[168, 
169]. In both low and high-risk culturing environments, we found a time-dependent 
increase of CD36, CD14 and SRA-1 positive monocyte-derived populations.  Finally, 
we assessed the mechanical strength of fibronectin in the TE early lesion disease model 
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using bacterial fibronectin-binding peptide 5 (Fn-BPA5) which is able to bind to 
relaxed fibers, representing an indirect indicator of collagen I deposition in the 
ECM[170]. 
  
 
Figure 3. Graphical abstract: human cell-based tissue engineered small-caliber vessels for investigating atheroma 
development. 
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2.2 Material and methods 
 
2.2.1  Isolation of endothelial cells and myofibroblasts  
 
Human umbilical vein endothelial cells (HUVECs) and myofibroblasts (HUVM) were 
isolated from human umbilical cords. The tissues were processed following the 
guidelines described in the ethical allowance from Kantonale Ethikkommission Zürich 
(KEK-Stv-21-2006). Umbilical cords were stored at 4°C in Dulbecco's Modified 
Eagle's Medium (DMEM, Sigma) prepared with 10% Fetal Bovine Serum (FBS, 
Gibco), 1% GlutaMax (Gibco) and 1% penicillin/streptomycin (Penn/Strep, Gibco) for 
maximum 2h prior to processing. The umbilical vein was carefully extracted from the 
umbilical cord and the inner lumen was flashed twice with 1×PBS.  The adventitia 
layer was discarded and the intima layer was gently detached by incubation with a 
solution of 1mg/ml collagenase/dispase (Roche) for 30 min in 1×PBS. The endothelial 
cells were collected by flashing 12 ml of M200 medium (Gibco) with low serum 
growth supplement (Gibco) and distributed in a gelatin coated 6 well plate. The 
endothelial cells were maintained in supplemented M200 medium for two weeks at 
37°C, 5% CO2 and 95% humidity and the medium was changed every 72h. The isolated 
endothelial cells were sub-cultured in larger vessels at about 80% confluence. The 
remaining media layer was minced into small pieces of approximately 2mm length and 
let adhere for 10min on the bottom of a petri dish. The tunica media fragments were 
then covered in DMEM medium and maintained at 37°C, 5% CO2 and 95% humidity.  
The medium was replaced every 48h. After about 20 days myofibroblasts sprouting 
from the minced pieces reached about 80% confluence and were ready for sub-
culturing. 
 
2.2.2  Cell culture  
 
HUVECs were cultured in supplemented M200 and the medium was replaced every 
48h.  At about 80% confluence HUVECs were detached using trypsin 0.5% (Sigma) 
for 2 min and seeded at a density of 5,000 cells/cm2. HUVECs used for this study were 
expanded up to passage 2. HUVM were cultured in DMEM medium with 10% FBS 
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and 1% GlutaMax and the medium was replaced every 48-72h. For sub-culturing, 
HUVM were detached using trypsin 0.5% for 4 min and seeded at a cell density of 
4,000 cells/cm2. HUVM were expanded up to passage 5 prior to use for the experiments 
in this study. Human monocytic leukemia cell line (thp-1) isolated from the peripheral 
blood of a 1-year-old human male with acute monocytic leukemia, were purchased 
from Sigma. Thp-1 cells were cultured in suspension in xVivo15 medium and the 
medium was replaced every 2-3 days. Thp-1 cells were seeded at a density of 100,000 
cells/ml and sub-cultured at a density of 800,000 cells/ml.  
 
2.2.3  Scaffold preparation  
 
Biodegradable tubular scaffold matrices (length 1.5 cm and inner diameter 0.5 mm) 
were fabricated using non-woven polyglycolic-acid meshes (PGA, Cellon) coated with 
a 1.5% solution of poly-4-hydroxybutyrate (P4HB, TEPHA Inc.) in tetrahydrofuran 
(THF, Sigma). Briefly, 1mm thick PGA foils were cut in rectangular shapes, brushed 
with the P4HB/THF solution on both sides and rolled onto an aluminum wire with an 
external diameter of 0.5 mm. The tubular shape was obtained by heat-sewing the rolled 
rectangular meshes at 80°C. The scaffolds were sterilized in 70% ethanol for 30 min 
and let dry O.N. in a sterile cell culture hood. Both extremities of the tubular mesh were 
glued on the fluid with a biocompatible 12.5% polyurethane (Sigma) glue in THF. 
 
2.2.4  Tissue engineering  
 
Scaffolds and fluidic chambers were sterilized with ethylene oxide plasma treatment, 
washed with sterile 1×PBS for 30 min and equilibrated O.N. in DMEM medium. 
HUVMs were seeded at a cell density of 6×106 cells/cm2 using a fibrinogen: thrombin 
1:1 hydrogel as cell carrier [171] and maintained for 6 days in static culture with 
DMEM medium. The medium was replaced every 24h. The chamber was then 
assembled for dynamic culture and maintained in a pulsatile flow generated by the 
Masterflex®exr peristaltic pump (ColeParmer, USA) with a velocity of 0.02 m/s for 
additional 6 days. During dynamic culture the DMEM medium was replaced every 48h 
and additioned with 1mM L-Ascorbic acid 2-phosphate sesquimagnesium (A2P). 
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 HUVECs were seeded in the vessel lumen at a cell density of 1×105 cells/cm2 using a 
25G needle. After a short static incubation period of 24h in DMEM:M200 (1:1) 
medium, vascular constructs were exposed to dynamic culture in DMEM:M200 
additioned with 1mM A2P for further 5 days. The tissue engineered mini-vessels were 
perfused for the 5 following weeks in DMEM: M200: xVivo15 (1:1:1) medium 
enriched with either (i) 190 mg/dl LDL (Lee Biosolutions) and 7x105 THP-1/ml or (ii) 
with 40 mg/dl of LDL and 5x105 THP-1/ml. The medium was replaced every 48h.  
 
2.2.5  Design and CFD of the fluidic chamber 
 
The fluidic chamber was designed using the 123D design software (Autodesk) and the 
resulting stereo lithography interface format (STL) file was used to manufacture the 
chamber using computer numerical controlled (CNC) milling. The chamber was milled 
in poly-methyl methacrylate while the external frame in aluminum. Details on the 
chamber design are described in Figure 5. For the computational fluid analysis (CFD) 
the chamber geometry was processed using the platform SimScale 
(https://www.simscale.com ). The geometry mesh operation was conducted using the 
meshing algorithm Hex-dominant automatic, specific for internal flow. The fluid 
dynamic simulation was conducted on the obtained polyhedral mesh considering the 
system as incompressible fluid-based steady-state on a laminar turbulence model. The    
kinematic viscosity of the fluid of 9.3379e-7 m2/s and a fluid density of 997.33 kg/m3.  
The velocity at the flow inlet was set as 0.02 m/s. The solution fields were prost-
processed in SimScale and the simulation results are accessible at 
https://www.simscale.com/projects/bf2af267032049/flow_in_a_chamber/ . 
 
 
2.2.6  Flow cytometry  
  
The tissue engineered small-caliber vessels were digested with 1mg/ml 
collagenase/dispase solution in 1×PBS for 15min at 37°C under continuous agitation. 
DNase1 was added to the cell suspension for at a final concentration of 0.1 mg/ml and 
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the tissues where incubate for additional 30 min. Cells were gently pipetted through 
cell strainers with the mesh size of 100 µm and through a 40 µm strainer (Falcon) and 
incubated for 5min at 4°C with magnetic beads coated with anti CD45 antibodies, 
according to the provider instructions (MACS Miltenyi Biotec). CD45+ cells were 
magnetically sorted, stained with Zombie Aqua™ fixable viability kit (BioLegend) for 
5min and fixed over night at 4°C in a 1% Paraformaldehyde (PFA, Sigma) solution in 
1×PBS. The single cell suspension was stained for 15min at room temperature in 
Fluorescence-activated cell sorting (FACS) buffer prepared with 5% FBS and 0.01% 
NaN3 (Sigma) in 1×PBS with an optimized FACS antibody panel including: CD14-
PerCP (#325631, Biolegend), CD16-Alexa 700 (#360717, Biolegend), CD11b-
Alexa594 (#101254, Bioloegend), CD11c-PE-Cy5 (#301609, Biolegend), CD36-
BV605 (#563518, Becton Dickinson) and SRA-1-PE (#REA460, MACS Miltenyi 
Biotec). Each antibody was previously titrated to establish the optimal working 
concentration. Samples were acquired using LSR Fortessa analyzer (Becton 
Dickinson) and signal compensation was performed using OneComp eBeads 
(eBioscience). 
 
2.2.7  the vi-SNE workflow  
 
The Flow Cytometry Standard (FCS) files obtained from the FACS analysis were pre-
processed using the software Flowjo (FlowJo, LLC). First, the cell populations of 
interest were gated according to forward and side scatter parameters (FSC and SSC). 
Second, singlets and Zombie Aqua™ dye negative events were selected, representing 
the living cell population of interest. Data post-processing was performed using the R 
platform and the Cytofkit package. Briefly, pre-processed FCS files from each sample 
were loaded onto Cytofkit, randomly down-sampled to 1,000 events (ceil; n=1,000) 
and computed using t-Distributed Stochastic Neighbor Embedding (t-SNE) 
algorithm[172]. Each event recorded was positioned in a specific location of the high-
dimensional space. The output was a vi-SNE biaxial plot where distances between 
events are representatives of cell proximity in high-dimensional rather than two-
dimensional space. The proximity between events is based on similarities in surface 
marker expression levels. Different myeloid subsets were positioned in separate 
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regions in high-dimensional space according to surface marker similarities. Automatic 
gating of myeloid subsets was performed through a preliminary clustering step with 
PhenoGraph algorithm (k=42) and a following metaclustering step with FlowSOM 
algorithm (k=10). The output of the above-described vi-SNE workflow is a vi-SNE 
map for each sample analyzed using FACS. Different biological replicates from each 
sample were combined to obtain a cumulative vi-SNE map. 
 
2.2.8  Immunofluorescence  
 
The tissue engineered vessels were harvested, washed 3 times in 1×PBS and transferred 
O.N. at 4°C in a 4% PFA solution in 1×PBS. The samples were then washed in 1×PBS, 
transferred in a 25% sucrose (Sigma) solution for 6h at 4°C and embedded in OCT 
matrix (CellPath). The vessels were then cryopreserved at -20°C until usage. Slices of 
5µm were cut, rehydrated in 1×PBS for 15min and stained with primary antibody 
vascular endothelial cadherin (#PA5-19612, Invitrogen) for 1h at 37 °C. Secondary 
antibody (anti-rabbit #A11008, Life Technologies) and phalloidin (#A12381, Life 
technologies) staining was performed for 1h at 37 °C. Nuclei were counterstained with 
DAPI (10 µg/ml) and the slides were mounted in Vectaschield® (Vector Laboratories). 
Images were acquired with the confocal microscope (Leica SP8). Image post-
processing, specifically the choice of appropriate pseudo-colors, was performed using 
ImageJ. 
 
2.2.9  Fn-BPA analysis   
 
For the Fn-BPA staining, cryopreserved slides were rehydrated for 15 min in PBS and 
incubated for 1h in 10 µg/ml of FnBPA5-Alexa- 488 (ETH, Prof. Vogel’s lab) peptide. 
The stained slides were washed 3 times in 1×PBS and stained with anti-fibronectin 
(#ab2413, Abcam) for 1h at R.T. followed by 3 washes in 1×PBS 1h at room 
temperature of secondary antibody staining (#ab6564, abcam). Nuclei were 
counterstained with DAPI (10 µg/ml) and mounted in Vectaschield®. Samples were 
imaged with an Olympus FV 1000 confocal microscope (Olympus AG, Switzerland) 
and Images were analyzed using Fiji-ImageJ. For investigating the Fn fibers in the TE 
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construct, the pixel area of FnBPA5-Alexa-488 signal intensity and of Fn-Cy intensity 
was calculated for each fiber. A mean of 10 fibers was imaged per experiment. 
 
2.2.10  Statistical analysis   
 
vi-SNE cluster counts, cluster median fluorescence intensity (MFI) and FnBPA5-
Alexa-488 signal intensity vs of Fn-Cy5 intensity were analyzed using multiple 
comparison analysis. First, Gaussian distribution of the data was confirmed with 
Shapiro-Wilk normality test. Second, repeated measures (RM) two-way ANOVA with 
Sidak’s multiple comparison test was applied. All statistical analyses were performed 
with GraphPad Prism Version 7, GraphPad Software, San Diego, CA, USA). 
Significance was accepted at p<0.05. All data are presented as mean ± s.d.. 
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2.3 Results 
 
2.3.1 Selection of the optimal tissue engineered vessel 
diameter and culturing settings 
 
To bioengineer a culturing microenvironment fulfilling the native coronary arteries 
physiology we followed a twofold strategy. First, we investigated the optimal diameter 
that the TE vessel needed to have in order to develop a similar wall shear stress (WSS) 
to the one of coronary arteries using Masterflex®exr peristaltic pump. Second, we 
studied the flow turbulence within the fluidic chamber in order to establish a linear 
flow as starting condition for the computational fluid dynamic simulation.  To study 
the intra-vessel WSS we investigated the flow velocity for each setting of the dynamic 
system employed (1-10). Therefore, we calculated the wall shear stress according to 
the formula below derived from the Newton’s law.  ! = # ∙ % 
 
Where t  is the shear stress measured in Pa, g is the shear rate measured in s-1 and h is 
the dynamic viscosity of the fluid measured in Pa·s. The shear rate of a flow in a pipe 
is calculated with the formula: 
 # = 8' ( 
 
where v is the linear fluid velocity measured in m/s and d is the inside diameter of the 
vessel. Finally, the linear fluid velocity v is related to the volumetric flow rate and it 
is calculated with the following formula. 
 	' = * +	 
 
Where Q is the volumetric flow rate measured in m3/s and A is the area of the cross-
sectional vessel area. We calculated the WSS values for each of the possible vessel 
diameter combined with each available setting of the bioreactor system employed 
(Table 2, Figure 4). From the WSS evaluation we selected the vessel diameter of 0.5 
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mm. To choose the best culturing parameters and in order to avoid bioreactor settings 
in which the flow is unstable and transitioning from linear to turbulent we calculated 
the Reynold’s number for each setting (Table 3). For a flow in a pipe (or vessel) the 
Reynold’s number (Re) is derived from the equation below. 
 ,- = 	*./0+  
 
where Q is the volumetric flow rate measured in m3·s, DH is the inner diameter of the 
pipe measured in m, v is the mean velocity of the fluid in m/s and A is the pipe’s cross-
sectional area in m2. Considering that the blood flow in the human coronary arteries 
reaches a velocity of about 5ml/min [173] and that, according to the Reynold’s number, 
the flow resulted linear at that velocity in our system, we selected parameter 3.  
 
 
Table 2. Wall shear stress for each vessel caliber and peristaltic pump setting. 
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Table 3. Reynold’s number for each setting of the peristaltic pump. 
 
 
 
Figure 4. Wall shear stress for each vessel caliber and 
peristaltic pump setting. 
 
 
2.3.2 Design and computational fluid dynamic model 
of the fluidic chamber 
 
We designed a fluidic chamber that could bear the simultaneous co-culture of 16 
vessels (Figure 5). We investigated the flow within the empty chamber to verify the 
presence of equal culturing conditions for each tissue engineered vessel. To do so, we 
processed the geometry of the inner fluid volume (Figure 5d) with the Hex-dominant 
1 2 3 4 5 6 7 8 9 10
0
10
20
30
40
setting
W
SS
 [P
a]
4 mm
2 mm
1 mm
0.5 mm
 
 
 36 
automatic mesh operation and we obtained a mesh of 1'588’550 nodes, 4’400'442 faces 
subdivided in 1’355'466 hexahedra, 8’861 prisms and 42158 polyhedra. For a 
successful simulation, we considered the system as linear, steady-state with 
incompressible fluid and established as a boundary condition the inlet flow velocity at 
0.02 m/s. We simulated the first 100s of flow in the chamber and we imaged the 
simulation environment every 20s (Figure 6). We observed that the flow speed at the 
steady state is similar in every nozzle, being about 0.024 m/s, and is similar to the inlet 
flow velocity of 0.02 m/s (Figure 6a). The hypothesis of identical culturing condition 
can be proven also to pressure and shear stress, considering the identical values at the 
nozzles of c.a. 1.5 Pa and 2×10-4 Pa respectively (Figure 6 b, c).  
 
 
 
 
Figure 5. Fluidic chamber design and inner flow model. (a) Design of the fluidic chamber for the production of 
small-caliber TE vessels. (b, c) 3D view of the fluidic chamber in its assemblable components. (d) Inner flow model 
representing the volume occupied by the fluid within the chamber. 
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Figure 6. Simulation of the inner flow. The inner flow forces are reported here at the beginning (20s time-point, left 
side) and at the end (100s time-point, right side) of the fluid dynamic simulation. (a) Flow velocity, (b) pressure and 
(c) wall shear stress are reported. 
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2.3.3 Tissue engineered vessels architecture 
 
The tissue engineered vessels produced within the chamber were sampled and 
inspected at the end of the dynamic culturing process.  The vessels show excellent 
tissue formation (Figure 7a) characterized by high cellular density with extensive 
myofibroblast growth within the scaffold (Figure 7c, d) and endothelial cells forming 
a layer facing the inner lumen (Figure 7c). After 5 weeks of culture most of the vessels 
showed the formation of a thickened area close to the vessel outlet (Figure 7b). 
 
 
Figure 7.  Small-caliber tissue engineered vessels. (a) TE vessel biofabricated using the fluidic chamber. Scale bar 
1.5mm. (b) TE vessel after 5 weeks of culture in high-risk condition. Scale bar 1.5cm, (c, d) Vessel architecture with 
VE-Cadherin (VE-Cad) positive HUVECs and F-actin positive HUVMs. L = lumen. Scale bar 100 µm. 
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2.3.4 Time-dependent study of THP-1 derived 
populations within the TE vessels 
 
To verify weather monocytes were extravasating in the TE vessel sub-endothelium and 
differentiating into phagocytic populations, we investigated the THP-1 derived 
populations within the vessel at different time points. We found that CD45+ cells not 
only were present in the vessel, but also they differentiated into scavenger populations 
characterized by high expression levels of CD36. Importantly, we compared the 
CD45+ populations within tissue engineered vessels cultured in a high-risk and low-
risk environment. In both culturing conditions, we found that two populations, 4 and 
7, were the most represented and together covered about 80% of the total number of 
events recorded (Figure 8). Importantly, population 4 retained a clear phagocytic 
phenotype, expressing CD11b+, SRA-1+, CD14high and CD36high. Population 7 shows 
high expression of CD14 and CD36 but is negative for CD11b (Figure 9). We observed 
a significant increase of population 4 over-time in vessels cultured in both high-risk 
(p=0.006) and low-risk (p<0.001) condition while population 7 displayed no variation 
(Figure 8c). In cell-free scaffold controls cultured in both conditions we did not find 
any significant change over-time in population 4 and 7, despite we observed a tendency 
of population 4 to increase in cell-free scaffold maintained in the high-risk condition 
and of population 7 in scaffold cultured in low- risk condition (Figure 8c). When we 
took a deeper look in the median fluorescence intensity (MFI) time-dependent changes 
we noticed that population 4 showed a significant gain of CD36 from week 3 to 4 
(p<0.001 both low and high-risk) and from week 4 to 5 (p<0.001 only high-risk) 
(Figure 10a). Moreover, we observed that population 7 had an over-time fluctuation of 
surface expression levels of CD14 and CD36, displaying their highest MFI at 4weeks 
(Figure 10b).  
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Figure 8. Intra-vessel THP-1 derived cell populations over time. vi-SNE maps showing THP-1 derived populations 
from vessels cultured in low-risk (a) and high-risk (b) condition. 3 weeks, 4 weeks and 5 weeks culturing time-points 
are shown to the left, center and right respectively. n=3. A total number of 2000 events is shown in each vi-SNE map 
presented. (c) Quantification of each THP-1 derived intra-vessel population over the modeling time. **p=0.006, 
***p<0.001 
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Figure 9. Surface markers expression profile. Median 
fluorescence intensity for each marker analyzed in each 
THP-1 derived cell population. 
 
 
Figure 10. MFI variation over time. Variation of the median fluorescence intensity during 
the disease modeling time in population 4 (a) and 7 (b) for both low-risk (left) and high-
risk (right) culturing condition. *p=0.05, **p=0.002, ***p<0.001 
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 2.3.5 Investigation of Fn tensional state over-time and 
condition 
 
 
To study the tensional state of fibronectin (Fn) in the extracellular matrix of the tissue 
engineered vessels we performed an investigation based on the use of the Fn-BPA5 
peptide. The latter intercalates in the loose fibers of Fn providing information on the 
fiber state in the tissue. We observed that immature, loose fibronectin fibers stained 
with Fn-BPA were significantly decreasing over-time in both high and low-risk 
condition (Figure 11b). Importantly, this process appeared to be faster in vessels 
cultured in low-risk condition where immature Fn showed a reduction of more than 3 
folds in a time gap of 3 weeks (p<0.001) (Figure 11b). In vessels cultured in high-risk 
condition such reduction of immature Fn was only observed after 4 weeks (p=0.01) 
(Figure 11b). From 4 weeks of culture on we reported no significant differences of 
immature Fn levels between high-risk and low-risk condition (Figure 11a). We showed 
that the decrease in immature Fn was concomitant with the formation of mature fibers 
(Figure 11a, b and c). Interestingly, after 5 weeks of culture mature fibers were 
significantly less in high-risk compared to low-risk condition (p=0.01) (Figure 11a). 
We then compared the results of immature and mature Fn levels from the TE early-
lesion vessels to those obtained from late-stage plaques isolated from human carotid 
explants. We observed that human late-stage plaques were characterized by persistence 
of immature Fn and low levels of mature fibers at the plaque side meanwhile displaying 
a reverse pattern in the rest of the vessel (Figure 11e, f). Overall, we observed that till 
3 weeks of culture there was no clear prevalence of mature fibers over immature Fn, 
independently from the culturing condition, while at week 4 and 5 mature Fn 
significantly prevailed over immature fibers (p<0.001) (Figure 11c). 
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Figure 11. Investigation of fibronectin tensional state over time. Fn-BPA and fibronectin signal intensity are shown 
and results compared between low-risk and high-risk culturing conditions (a, b and c). cross-section of a tissue 
engineered vessel at the end of the modeling process. Scale bar 200µm (d). Fn-BPA and Fn intensities are compared to 
the results obtained from human atherosclerotic plaques isolated from carotid explants and from the respective native 
carotid vessel. Scale bar 200µm (e, f). 
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2.4 Discussion 
 
 
With the fabrication of a fluidic chamber hosting multiple tissue engineered vessels we 
aimed at developing an upscalable early-stage atherosclerosis disease model. Such 
model is based on a dynamic triple co-culture supported by PGA, a biodegradable 
scaffold material. Several in vitro models of early-stage atherosclerosis are available 
but they are mainly based on static 2D co-culture systems[137, 174]. Recently, our lab 
developed a 3D human cell-based system to mimic early disease stages [6]. Despite the 
success in modeling early events as endothelial activation, monocyte recruitment and 
sub-endothelial extravasation, this model showed several weaknesses. In detail, the 3D 
model (i) investigated early atherosclerosis events spanning only 24h after vessel tissue 
engineering, (ii) did not employ monocyte cell titer and LDL concentration in the 
culture medium comparable to pathophysiological/physiological environment, (iii) did 
not allow simultaneous co-culture of multiple tissue engineered constructs and (iv) did 
not investigate flow velocity, WSS and fluid pressure in order to fine-tune and optimize 
the culturing conditions.  
To improve such promising 3D disease model, we started by investigating the 
vessel dimension to employ for the early-lesion model. First, we studied the WSS that 
could be achieved with our dynamic flow propeller (settings from 1 to 10) at different 
putative vessel diameters. Diameters spanning from 4mm, average proximal diameter 
of the right coronary artery, to 0.5mm were investigated[175]. Second, we selected the 
vessel diameter that alone could allow us to possibly set up different WSS scenarios. 
We chose to biofabricate vessels of 0.5 mm in diameter, which is also close the average 
diameter of the human coronary arterial tree, calculated as cross-sectional area of the 
vasculature from proximal to distal (0.93+/-0.26 mm)[176]. Such diameter coupled 
with our peristaltic pup settings allows to model from low (0.57±0.23 Pa) to medium 
(0.18±0.47 Pa) WSS environments [177] by fine tuning flow velocity. To select the 
best culturing flow environment, we investigated the status of the medium flow at each 
setting, considering the chosen vessel diameter. To do so, we calculated the Reynold’s 
number (Re) for each setting. Re is a fluid dynamics dimensionless quantity allowing 
the prediction of flow patterns in different fluid flow situations. In detail, for Re ≤ 1000 
the flow is considered laminar while for higher Re values the flow becomes either 
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transitional (1000 ≤ Re ≤ 2000) or turbulent (Re ≥ 2000). We showed that the flow 
remains linear for setting 1 to 8 (flow velocity 0.3-20 ml/min) and becomes transitional 
at setting 9 (flow velocity of 23 ml/min) and 10 (26 flow velocity of ml/min). 
In order to simultaneously culture multiple tissue engineered vessels, we 
designed and fabricated an easy-to-assemble fluidic chamber. We hypothesized that 
each vessel was subjected to equal force load. To test this hypothesis, we performed a 
computational fluid dynamic simulation using the chamber geometry.  We considered 
the simulation environment as steady-state with incompressible fluid and as boundary 
condition we set a flow velocity at the chamber inlet of 0.02 m/s (corresponding to 
setting number 3, 5ml/min). We confirmed our hypothesis and we identified the 
velocity, pressure and WSS at the TE vessel inlet as 0.024 m/s, 1.5 Pa and 2×10-4 Pa 
respectively. A velocity of c.a. 0.02 m/s is comparable to the average blood flow 
velocity in human coronary arteries[178] . A low WSS as the one simulated at the inlet 
of the tissue engineered vessel is associated with plaque formation and progression [177, 
179]. 
Once the dynamic culture system was set up we proceeded with the 
bioengineering experiments. The TE vessels obtained after 3-weeks of tissue 
engineering protocol showed extensive tissue formation and the deposition of an 
endothelial cell layer in the vessel lumen. The tissue engineered constructs were kept 
in dynamic culture for further 5 weeks. In these additional 5weeks the constructs were 
cultured in two different conditions modeling either and athero-prone (high-risk) or a 
normal (low-risk) condition [166, 167]. Interestingly, after these additional 5 weeks of 
culturing (early atheroslcerosis modeling period) we observed the accumulation of a 
cellular plaque close to each vessel flow outlet, independently from the culturing 
condition. Further CFD simulations considering a fully loaded fluidic chamber and 
detailed immunofluorescence-based investigations are needed to elucidate the 
dynamics triggering the formation of such cellular structures. 
 To investigate the effects exerted from the different culturing conditions on the 
TE vessels we conducted a twofold study. First, we inquired the THP-1 derived 
populations accumulating over time in the vascular sub-endothelium using flow 
cytometry. Second, we studied possible changes in the structure of ECM protein 
fibronectin (from immature to mature) triggered by the culturing conditions. From the 
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FACS analysis we identified 7 putative THP-1 derived cell populations, probably 
encompassing various stages of THP-1 functional differentiation[180]. We reported 
the presence of two cell populations that appeared to be the most abundant, population 
4 and 7, both with high CD36 expression levels. We hypothesize that population 7 
represents the circulating THP-1, being negative for CD16, CD11b and CD11c but 
positive for CD14 and CD36 [181-183] while population 4 are THP-1 derived 
macrophages with high surface levels of  CD36 and being positive for CD11b and 
SRA-1 [183, 184]. Both populations show high expression levels of CD14, that is 
described to be CD14 was described as monocyte/ macrophage differentiation antigen 
that is generally lost or reduced during monocyte to macrophage differentiation [185]. 
Recently CD14 role has been discovered to be involved in phagocytic clearance of 
apoptotic cells[186, 187]. This justifies the high levels of CD14 measured on the surface 
of putative THP-1 derived macrophages. Interestingly but not surprisingly, we noticed 
an increase of population 4 (putative macrophage population) over-time within the TE 
vessel in both conditions. Despite population 7 did not show any variation in number 
over time in both culturing environment, we reported fluctuations in surface expression 
of CD14 and CD36 in low-risk condition, but not in high-risk. This might be linked to 
the fact that the high LDL concentration prevented flexible exposure of different 
surface proteins, driving the differentiation of population 7 (putative monocytes) 
directly towards macrophage fate and excluding possible other differentiation paths as 
previously shown [188, 189]. From the flow cytometry data we concluded that, in such 
early stages of plaque formation, no LDL-driven change in surface antigen expression 
is noticeable in THP-1-derived populations recruited in the sub-endothelium. As 
formerly known and previously mentioned, high circulating LDL levels are not the sole 
risk factor to initiate and drive plaque development. Such condition might be of 
relevance for the differentiation of monocyte population during later stages of disease 
development and incentivize plaque progression rather than regression[189]. Further 
experiments are needed to elucidate at which stage of plaque development high 
circulating LDL concentrations can influence population remodeling in the tunica 
intima. 
 Finally, we investigated the tensional state of fibronectin over time aiming at 
identifying possible condition-dependent change in fibronectin maturation. Fibronectin 
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is one of the most abundant ECM proteins [190, 191] serving as docking site for several 
other ECM components. In particular, it has been demonstrated that relaxed, immature 
Fn fibers serve as nucleation site for collagen and are generally localized in collagen I 
rich areas[170, 192].We supported these findings by showing for the first time that 
relaxed Fn is present in high concentration in human late-stage atherosclerotic plaques, 
well known to show an ECM rich collagen I [193]. We measured the levels of relaxed 
fibronectin at the end of the bioengineering process (T0) and we found Fn-BPA 
(binding to relaxed Fn) intensity was significantly higher compared to native human 
carotids, indicating a still immature ECM composition in the bioengineered constructs. 
Furthermore, we observed that the levels of Fn-BPA in vessels cultured in high-risk 
conditions where higher and decreasing slower compared to low-risk condition. This 
might indicate that high LDL concentrations and high monocyte titer negatively 
influence the maturation of ECM matrix and provide the basis for the formation of an 
ECM rich in collagen I. Longer culture periods in high-risk environment could reveal 
weather this hypothesis is correct.  
 In conclusion, despite this model represents the most advanced early-stage 
atherosclerosis disease model, there are still some hurdles to overcome. Among them 
there is (i) the need of performing computational fluid dynamic simulations considering 
the fully loaded chamber (chamber + vessels) in order to deepen the understanding of 
the flow in the TE vessel during the biofabrication and disease modeling processes. 
Additionally, (ii) changes in fluid viscosity due to variation in LDL concentration have 
to be considered to optimize the simulation results.  
  
  
 
 
 
 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
Chapter 3 
Adapted from: 
Mallone, A., Stenger C., Von Eckardstein A., Hoerstrup S.P. and Weber B. (2018) Biofabricating atherosclerotic 
plaques: In vitro engineering of a three-dimensional human fibroatheroma model. Biometerials. doi: 
10.1016/j.biomaterials.2017.09.034. 
 
In vitro bioengineering of the late lesion 
 
 
3.1 Introduction  
 
Among different plaque stages, the thin-cap fibroatheroma is the one most prone to 
rupture and to potentially cause thrombus formation and vessel obstruction [194]. The 
fibroatheroma is characterized by the presence of a necrotic core, macrophage-derived 
foam cells and dendritic cells all being enriched with cholesterol and embedded in a 
collagenous matrix surrounded by a thin layer of fibrotic cells [70, 71]. In the present 
study, we introduce a bioengineered in vitro model of fibroatheroma that we call 
pseudo plaque (ps-plaque). The ps-plaque architecture is characterized by a spheroid 
core of monocytes, macrophages and dendritic cells embedded in a collagenous and 
lipid-rich matrix, surrounded by a thin layer of myofibroblasts. In order to investigate 
a possible source for model up-scaling we biofabricated ps-plaques using either blood-
derived myeloid cells or cells from the thp-1 cell line. We explored the similarities in 
surface antigen expression patterns of myeloid populations from ps-plaques and human 
carotid plaques isolated from patients undergoing carotid endarterectomy. 
Additionally, we compared the expression levels of key pro-inflammatory and 
remodeling gene-targets in both plaque types. We found similarities in population 
distribution and gene expression profiles between ps-plaques and human samples. 
Finally, we used the ps-plaque to investigate the role of LDL in plaque population 
remodeling and cell viability. With this work, we introduce a new technology for 
investigating atherosclerosis pathomechanisms, aiming at providing a novel human 
cell-based platform for drug design and high-throughput screening. 
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Figure 12. Graphical abstract: In vitro engineering of a three-dimensional human fibroatheroma model. 
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3.2 Material and methods 
 
3.2.1  Isolation of myeloid cells from blood  
 
Myeloid cells were isolated from human blood using a double gradient centrifugation. 
The blood was provided by the Zurich blood bank (Blutspende Zürich – Nr.6676) and 
maintained at room temperature in slow rocking motion until processing. First, 20ml 
of blood from each donor were diluted 1:2 with 1× Phosphate Buffer Saline (PBS, 
Sigma) at room temperature and layered onto a Ficoll solution (1.077 g/ml, Sigma). 
Samples were then centrifuged at 400g for 30min without break. Second, a 46% iso-
osmotic Percoll gradient was performed to separate the lymphocytes from the 
peripheral blood mononuclear cells (PBMCs) as previously described [195]. Briefly, 
the buffy coat was re-suspended in 20ml of xVivo15 chemically defined medium 
(Lonza) without red phenol and carefully layered on top of a Percoll solution prepared 
with 50% Roswell Park Memorial Institute (RPMI) medium with red phenol (Sigma), 
46% Percoll (GE Healthcare) and 4% 1×PBS (Sigma). The second gradient was 
centrifuged at 550g for 30min without break and the white cell ring at the interphase 
was collected for further processing.  
 
3.2.2  Myofibroblasts isolation  
 
 Human umbilical vein myofibroblasts (HUVM) were isolated from human umbilical 
cords. The tissues were processed in accordance to the ethical permit released by the 
Kantonale Ethikkommission Zürich (KEK-Stv-21-2006). Briefly, umbilical cords were 
stored after labor at 4°C in Dulbecco's Modified Eagle's Medium (DMEM, Sigma) 
prepared with 10% Fetal Bovine Serum (FBS, Gibco), 1% GlutaMax (Gibco) and 1% 
penicillin/streptomycin (Penn/Strep, Gibco) for maximum 2h prior to processing. The 
umbilical vein was carefully extracted from the umbilical cord and the inner lumen was 
flashed twice with 1×PBS. The adventitia layer was peeled off with the help of forceps 
and scalpel. The intima layer was removed by incubating the inner lumen for 30min in 
a 1mg/ml collagenase/dispase (Roche) solution in 1×PBS. The remaining endothelial 
cells were washed out from the lumen with 1×PBS. The remaining media layer was 
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minced into small pieces of approximately 2mm length and let adhere for 10min on the 
bottom of a petri dish. The tunica media fragments were then covered in DMEM 
medium and maintained at 37°C, 5% CO2 and 95% humidity.  The medium was 
replaced every 48h. After about 20 days myofibroblasts sprouting from the minced 
pieces reached about 80% confluence and were ready for sub-culturing. 
 
3.2.3  Cell culture  
 
HUVM were cultured in DMEM medium with 10% FBS and 1% GlutaMax and the 
medium was replaced every 48-72h. For sub-culturing, HUVM were detached using 
trypsin 0.5% (Sigma) for 4 min and seeded at a cell density of 4,000 cells/cm2. HUVM 
were expanded up to passage 5 prior to use for the experiments in this study. Human 
monocytic leukemia cell line (thp-1) isolated from the peripheral blood of a 1-year-old 
human male with acute monocytic leukemia, were purchased from Sigma. Thp-1 cells 
were cultured in suspension in xVivo15 medium and the medium was replaced every 
2-3 days. Thp-1 cells were seeded at a density of 100,000 cells/ml and sub-cultured at 
a density of 800,000 cells/ml.  
 
3.2.4  In vivo models  
 
The pseudo-plaque production pipeline encompasses three steps: differentiation, 
priming and hanging-drop. First, fresh blood-derived myeloid cells or thp-1 cells were 
seeded onto petri dishes for 72h and differentiated in chemically defined xVivo15 
medium with 10% FBS in order to achieve a macrophage/dendritic cell phenotype. To 
induce thp-1 differentiation 10ng/ml of phorbol 12-myristate 13-acetate (PMA, Sigma) 
were added to the culture medium. Second, a priming step was performed to obtain 
heterogeneous macrophage/dendritic cell populations with both pro-inflammatory and 
remodeling phenotypes. For this purpose, the differentiated cells were rinsed in 1×PBS 
and treated for 1h in xVivo15 medium with 10% FBS and 10ng/ml lipopolysaccharide 
(LPS, Sigma). Finally, the primed cells were transferred in hanging-drop culture. 
Briefly, adhesive myeloid-derived cells were mechanically detached by 20min 
incubation in 5mM Ethylenediaminetetraacetic acid (EDTA, Life Technologies) in 
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1×PBS at 4°C and gentle scraping. Cells were re-suspended at a cell density of 2.4 x 
106 cells/ml in presence of LDL 50µg/ml (LEE Biosolutions) in xVivo15 medium with 
10% FBS. Droplets of 10µl were pipetted on the lead of a 10cm diameter petri dish and 
kept in hanging-drop culture for 48h.  To the core of myeloid-derived cells assembled 
during the 48h incubation, an external layer of HUVM was added.  HUVM were 
prepared at a cell density of 4 x 105 cells/ml in DMEM medium, with or without 
50µg/ml LDL. 10µl of the cell suspension were carefully added to each pre-existing 
drop and cultured in hanging-drop for further 48h. 
 
3.2.5  2D co-culture  
 
Primed myeloid cells from blood or thp-1 origin were seeded in 24 well plates 
maintaining the same cell ratio used for the ps-plaque biofabrication (myeloid cells: 
myofibroblasts 6:1). In detail, about 300'000 primed myeloid cells were seeded with or 
without 50µg/ml LDL in each well in order to achieve a confluent cell layer. Cells were 
kept in xVivo15 medium with 10% FCS and in 2D culture for 48h. 50'000 
fibroblasts/well in DMEM medium (with or without 50µg/ml LDL) were then added 
on top of the myeloid cell layer and incubated for 48h to obtain a stratified 2D co-
culture system. 
 
3.2.6  Flow cytometry  
 
Biopsies of carotid branches were obtained from patients undergoing carotid 
endarterectomy and shunting, secondary to vascular stenosis (Ethik Kommission der 
Universität Witten/Herdecke – Nr.79/2012). Carotid plaques and biofabricated ps-
plaques were digested with 1mg/ml collagenase/dispase solution in 1×PBS for 15min 
at 37°C. Cells were gently pipetted through a cell strainer with the mesh size of 40µm 
(Falcon) and incubated for 5min at 4°C with magnetic beads coated with anti CD45 
antibodies, according to the provider instructions (MACS Miltenyi Biotec). CD45+ 
cells were magnetically sorted and stained with Zombie Aqua™ fixable viability kit 
(BioLegend) for 5min and fixed over night at 4°C in a 1% Paraformaldehyde (PFA, 
Sigma) solution in 1×PBS. The single cell suspension was stained for 15min at room 
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temperature in Fluorescence-activated cell sorting (FACS) buffer prepared with 5% 
FBS and 0.01% NaN3 (Sigma) in 1×PBS with an optimized FACS antibody panel 
including: CD14-PerCP (#325631, Biolegend), CD16-Alexa 700 (#360717, 
Biolegend), CD11b-Alexa594 (#101254, Bioloegend), CD11c-PE-Cy5 (#301609, 
Biolegend), CD36-BV605 (#563518, Becton Dickinson) and SRA-1-PE (#REA460, 
MACS Miltenyi Biotec). Each antibody was previously titrated to establish the optimal 
working concentration. Samples were acquired using LSR Fortessa analyzer (Becton 
Dickinson) and signal compensation was performed using OneComp eBeads 
(eBioscience). The FACS data were analyzed using the vi-SNE workflow as described 
in the previous chapter. 
 
3.2.8  Immunofluorescence  
 
Myofibroblasts were fixed for 20min in 4% PFA in 1×PBS and maintained in 1×PBS 
at 4°C until further processing and not more than 7 days. Cells were stained with the 
primary antibodies anti-alpha smooth muscle actin (αSMA, #ab7817, Abcam) and anti-
smooth muscle myosin heavy chain (SMMHC, #ab53219, Abcam) overnight at 4°C 
and with secondary antibodies (anti-mouse #715-605-151, Jackson Immuno Research; 
anti-rabbit #A11008, Life Technologies) and phalloidin (#A12381, Life technologies) 
for 1h at 37 °C. Nuclei were counterstained with DAPI and the slides were mounted in 
Vectaschield® (Vector Laboratories). The ps-plaques were carefully washed in 1×PBS 
and fixed in PFA as described above. Plaques were dehydrated overnight in a solution 
of 25% sucrose (Sigma) in 1×PBS, embedded in OCT matrix (CellPath) and stored at 
-20°C. Slices of 5µm were cut, rehydrated in 1×PBS for 15min and stained with 
primary antibodies: anti-Collagen type III (#ab7778, Abcam), anti-αSMA and anti-
CD45-PeCy5 (#304009, BioLegend) overnight at 4°C. Secondary antibody staining 
was performed (anti-mouse, 715-545-151, Jackson Immuno Research; anti-rabbit 
#A11008, Life Technologies) for 1h at 37°C. For the Filippin sections were quenched 
for 10min with 1.5mg/ml glycine (Sigma) in 1×PBS prior to addition of 250µg/ml 
Filippin III dye (Sigma) at room temperature for 2h. Sections were washed 3 times in 
1×PBS and nuclei were counterstained with propidium iodide 1mg/ml (BioLegend) for 
5min. Slides were mounted in Vectaschield®. Images were acquired in grey scale with 
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the confocal microscope (Leica SP8). Image post-processing, specifically the choice of 
appropriate pseudo-colors, was performed using ImageJ. 
 
3.2.9  TEM and SEM  
 
For scanning electron microscopy (SEM) and transmission electron microscopy 
(TEM), ps-plaques were fixed with a 2.5% glutaraldehyde solution in 0.1M sodium 
cacodylate (NaCaCo) and maintained O.N. at 4°C. For TEM samples were then washed 
2 times in 0.1M NaCaCo and further fixed for 1h in osmiumtetroxide. After 3 washes 
in 0.1M NaCaCo, a staining of s1h with 1% uranyl acetate in water was performed. 
Samples were further washed for 3 times in 0.1M NaCaCo, dehydrated with a EtOH 
gradient, embedded in Epon resin O.N. at 60°C and analyzed at the TEM (FEI Tecnai 
G2 Spirit). For SEM, the fixed ps-plaques were rinsed 3 times in PBS and incubated in 
osmiumtetroxide: PBS in 1:2 ratio for 30 minutes. Samples were dehydrated by 30 min 
incubation with 70% EtOH followed by 30 min incubation in EtOH 100%.  Finally, 
the samples were kept 1h in Hexamethyldisilazane and let dry overnight. Samples then 
stained in platinum blue 4nM at R.T. for 30 min and analyzed at the SEM (JEOL JSM-
6010 tungsten cathode scanning electron microscope). 
 
3.2.10  RT-qPCR  
 
Total RNA was extracted using the GenElute Mammalian Total RNA Kit (Sigma), 
following the manufacturer’s instructions. Reverse transcription was performed for 
each sample in a 20µl reaction mixture containing 1µg of RNA, 1×PCR buffer, 5mM 
MgCl2, 10mM of each dNTP, 0.625µM oligo d(T)16, 1.875µM random hexamers, 20U 
RNase inhibitor and 50U MuLV reverse transcriptase (all from Life Technologies). 
The conditions for the reverse transcription were the following: 25°C for 10min, 42°C 
for 1h, followed by 99°C for 5min. The resulting cDNA was amplified in duplicate by 
quantitative real-time PCR in 10µl reaction mixture with 200nM of each specific 
primer (Supplementary Table 2) and 1×Fast Syber Green qPCR MasterMix (Applied 
Biosystems). For the amplification reaction, StudioQuant 7 was used (Applied 
Biosystem). The amplification program was set as follows: 95°C for 5min, followed 
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by 40 cycles at 95°C for 10 s, 60°C for 15 s, 72°C for 20 s. GAPDH and 18S served as 
housekeeping genes and their amplification data were averaged and used for sample 
normalization. The software Excel (Microsoft) was used for the comparative 
quantification analysis. 
 
3.2.11  Ps-plaque viability assay  
 
Cell viability within the plaque was measured using CellTiter-Glo® 3D Cell Viability 
Assay (Promega). Briefly, the biofabricated plaques were washed in 1×PBS and 
dispensed in an opaque-walled 96 well plate (Costar). Each ps-plaque (1 plaque/well) 
was dispensed in 15µl of 1×PBS. Equal volume of CellTiter-Glo® 3D Reagent was 
added to each well for a final volume of 30µl. Luminescence was measured after a 
30min of incubation at room temperature with SPECTRAmax® Gemini-XS (Bucher 
biotech) and ATP levels were reported in relative luminescence units (RLU). 
 
3.2.12  Quantification of ps-plaque area and necrotic 
area  
 
For the measure of the plaque necrotic area, every plaque was stained for 40min in a 
solution of calcein (5µM) and eth-1 (15µM) from the LIVE/DEAD™ 
Viability/Cytotoxicity Kit, for mammalian cells (Life Technologies). Ps-plaques were 
imaged using an inverted microscope (Leica, DM IL LED) and post-processed in 
ImageJ. Briefly, images underwent color 2D Parallel iterative deconvolution using the 
Wiener Filter Preconditioned Landweber (WPL) method (Max number of iteration=5; 
Max number of threads2 =4). The results of the point of spread function obtained from 
the deconvolution were normalized and the green and red channels were thresholded 
with the MaxEntropy setting. The ps-plaque necrotic area was measured as necrotic 
area over alive area and indicated as percentage. Plaque dimension was measured using 
the bright field images of the plaque circular cross section. First, the image was 
converted to 8-bit format and tresholded with the MaxEntropy method. Second, the 
area of the particles was analyzed from objects with a dimension larger than 1,000px 
in order to exclude debris or single cells not belonging to the bioengineered plaque. 
Plaque area was reported in mm2. 
 
 
 57 
 
3.2.13  Statistical analyisis 
 
vi-SNE cluster counts and PCR comparative quantitations were analyzed using 
multiple comparison analysis. First, Gaussian distribution of the data was confirmed 
with Shapiro-Wilk normality test. Second, repeated measures (RM) two-way ANOVA 
with Tukey’s multiple comparison test was applied. Luminescence and necrotic area 
were analyzed with paired t-test. All statistical analyses were performed with GraphPad 
Prism Version 7, GraphPad Software, San Diego, CA, USA). Significance was 
accepted at p<0.05. All data are presented as mean ± s.d.. 
 
 
 
 
 
 
 
 
 
Table 4. Primer table. 
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3.3 Results 
 
3.3.1  Differentiation-priming strategy promotes 
population redistribution in cells from myeloid origin 
 
We established a two-step bioengineering method for the assembly of the ps-plaque 
(Figure 13a, 14 and 15). Myeloid cells isolated from freshly drawn blood and thp-1 
cells were differentiated towards macrophage/dendritic phenotype and primed with 
LPS to obtain a mixed population of pro-inflammatory and remodeling cell 
populations. The success of the differentiation-priming strategy was verified using a 
fluorescence-activated cell sorting (FACS) and the results were computed using 
dimensionality reduction and clustering algorithms, PhenoGraph and FlowSOM 
respectively [168]. With this technique, we identified 15 cell populations in the 
multidimensional space that we classified according to the differential expression 
levels of key surface markers (Figure 13c, 16, 17 and Table 5). In samples isolated 
from the blood we identified 4 over-represented populations: classical monocytes 
(Mocl), macrophages (Mφ1), pre-classical dendritic cells (pre-cDC) and an unknown 
myeloid progenitor population (Prog) (Fig. 1c; Supplementary Fig. 2). We monitored 
each population at the end of the differentiation-priming process and we observed a 
significant decrease in the unknown myeloid progenitors (p=0.005) coupled with a 
significant increase in pre-cDC (p=0.05) (Figure 13c). Additionally, we observed a 
priming-induced increase in CD11c surface levels within the pre-cDC population and 
in the myeloid progenitors (Figure 18 and 19). In cell samples from untreated thp-1 we 
observed an initial population distribution similar to the one found in blood samples. 
When we applied the priming process to thp-1 monocytes, we observed a significant 
reduction in the myeloid progenitors count (p<0.001). The latter was concomitant with 
a decrease in pre-cDC count (p<0.001) and the appearance of plasmacytoid dendritic 
cells (PDC) (Figure 20, 21 and 22). Furthermore, we observed that the priming process 
triggered the proliferation of classical monocytes (p<0.001) (Figure 20). We then 
analyzed the expression levels of pro-inflammatory and remodeling gene targets. In 
blood-derived cells we observed induction of CXCL10 (p<0.001), CCL17 (p<0.05), 
DC-SIGN (p<0.001) and SRB1 (p<0.001) upon treatment, indicating the overall 
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stronger induction of remodeling over pro-inflammatory genes (Figure 13b). When we 
analyzed the changes in thp-1 cells gene expression levels upon differentiation-priming 
we observed induction of CXCL10 (p=0.03), PTGS1 (p=0.05) and IL10 (p=0.01), 
indicating pro-inflammatory gene up-regulation over remodeling genes (Figure 23). 
  
Figure 13. Biofabricated human atherosclerotic plaque. (a) Schematic view of the ps-plaque assembly with 
blood-derived cells. (b) Expression profile of pro-inflammatory (left-white panel) and remodeling genes (right-
orange panel) over the differentiation-priming process. Data are reported in fold change over gene expression levels 
at the beginning of the differentiation-priming process. n=5; error bars indicate standard deviation; *p=0.05, 
***p<0.001. (c) vi-SNE maps indicating the cell populations at the beginning (Mo) and at the end (pMf/d) of the 
differentiation-priming process. n=7; 2,000 events per sample are reported; 14,000 events are shown in each vi-
SNE map. The stacked-bar chart indicates the percentage of events recorded in each population and summarizes 
the vi-SNE results. (d) Representative cross-section captured at the great circle of the spheroid showing inner 
architecture of the ps-plaque: HUVM (αSMA+, green) and myeloid cells (CD45+, magenta). Scale bar 100µm. (e) 
Collagen III and lipid accumulation in the ps-plaque. Scale bar 50µm. 
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Figure 14. Scanning electron microscopy of the ps-plaque. (a) SEM image of a ps-plaque. Scale bar 40µm. 
(b) Detail of the ps-plaque external surface. Scale bar 4µm. (c) Inner architecture of ps-plaque. Scale bar 4µm. 
With a detail (d, d1) showing macrophage/dendritic cells surfaces in contact with LDL cholesterol. Scale bar 
10 µm. 
 
 
 
Figure 15. Transmission electron microscopy of the ps-plaque. (a) TEM image of a ps-plaque showing 
accumulation of cholesterol crystals at the external surface. Scale bar 40µm. (b) Detail of the ps-plaque external 
surface. Apoptotic myofibroblast in contact with a cholesterol crystal. Scale bar 4µm. 
 
 
 61 
 
 
Figure 16. Identification of different myeloid subsets using the vi-SNE 
workflow. Samples are stained and acquired at the FACS analyzer. The 
resulting FCS files are processed to generate vi-SNE maps. Each cell recorded 
(single event) is positioned in a specific area of the high-dimensional space, here 
represented with commonly used FACS biaxial plots. Different myeloid subsets 
are positioned in separate regions of the high-dimensional space according to 
surface marker similarities. Distances between cells are representatives of cell 
proximity in high-dimensional rather than two-dimensional space. These 
myeloid subsets are automatically gated with using PhenoGraph and FlowSOM 
algorithms and identified in the vi-SNE map with different colors. 
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Figure 17. Surface expression levels of key markers in different myeloid subsets.15 cell populations 
were identified using the vi-SNE workflow. Each myeloid population retains a specific surface marker 
expression pattern indicated by the heat-map. The present heat-map represents the median fluorescence 
intensity of each marker in each myeloid subset and was computed using total of 112,000 events; n=7; 
2,000 randomly selected events for each sample analyzed (samples analyzed for both b and t plaques: Mo, 
pMf/d, T2, T2L). 
Table 5. Myeloid populations in ps-plaques and native carotid plaques. 
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Figure 18. Density plots from blood-derived cells before and after differentiation-priming process. (a) 
Density distribution of recorded events before (Mo) and after (pMf/d) the differentiation-priming process. 
Areas of high event density are depicted in red and areas with low event density in blue. n=7; 2,000 randomly 
selected events for each sample analyzed are shown (Mo and pMf/d). Therefore, in each vi-SNE maps 
14,000 events are plotted. (b) Expression level plots. Each vi-SNE map shows 112,000 events; n=7; 2,000 
randomly selected events for each sample analyzed (samples analyzed for both b and t plaques: Mo, pMf/d, 
T2, T2L). 
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Figure 19. vi-SNE maps from blood derived myeloid cells before and after priming procedure. Vi-SNE maps 
from each biological replicate (a-g) used to assemble the cumulative vi-SNE maps and cumulative density maps 
depicted in Figure 18 and Figure 13a. 
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Figure 20. Differentiation-priming effects on thp-1 cells. vi-SNE maps indicate different 
myeloid populations identified within thp-1 cells at the beginning (Mo) and at the end (pMf/d) 
of the differentiation-priming process. The part-of-whole graph shows the % of events and 
summarizes the vi-SNE results. n=7; 2,000 events per sample are reported. A total of 14,000 
events are shown in each vi-SNE map. 
 
 
 66 
 
 
 
 
 
 
 
 
 
Figure 21. Density plots from thp-1 cells before and after differentiation-priming process. (a) Density 
distribution of recorded events before (Mo) and after (pMf/d) the differentiation-priming process. Areas of 
high event density are depicted in red and areas with low event density in blue. In each vi-SNE maps 14,000 
events are plotted. n=7; 2,000 randomly selected events for each sample analyzed are shown (Mo and pMf/d).  
(b) Marker expression level plots. 
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Figure 22. vi-SNE maps from thp-1derived myeloid cells before and after priming procedure. Vi-SNE maps 
from each biological replicate (a-g) used to assemble the cumulative vi-SNE maps and cumulative density maps 
depicted in Figure 20 and 21. 
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Figure 23. Changes in gene expression profile of 
thp-1 cells upon differentiation–priming.  The 
expression profile of pro-inflammatory (left – white 
panel) and remodeling (right – orange panel) genes 
is reported in fold change over Mo expression levels 
(where fold change= 1). Data (n=5) were 
normalized on the averaged GAPDH and 18S 
expression levels. 
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3.3.2  Defining the gravity-guided biofabrication of 
human atherosclerotic plaques 
 
 Human primed myeloid cells and myofibroblasts (HUVM) were combined to establish 
a hanging-drop 3D co-culture system (Figure 13a, Figure 24). The newly established 
system resulted in α-SMA+ HUVM cells surrounding pre-existing myeloid CD45+ 
cell aggregates and forming a thin fibrotic layer around the bioengineered spheroid 
(Figure 13d). The generation of such stratified structure and compact HUVM layer was 
not observed in 2D co-culture systems when using the same cell-to-cell ratio (Figure 
25). Additionally, we observed the assembly of collagen clumps within the ps-plaque 
and intra-plaque accumulation of lipid aggregates (Figure 13e). We did not detect any 
extracellular collagen deposition in 2D co-culture systems. Collagen was rather 
retained in the intracellular space (Figure 25). 
 
 
 
 
 
Figure 24. Myofibroblasts characterization.  Myofibroblasts isolated from human umbilical vein express α- smooth 
muscle actin (α-SMA) and smooth muscle myosin heavy chain (SMMHC); scale bar 100µm.  
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 Figure 25. 2D microenvironmental co-culture. (a) 2D co-culture, experiment description. (b) 
The panel indicates the architecture of the 2D microenviroment where myofibroblasts appear 
insufficient in forming a confluent layer on top of myeloid cells.  Detail d1 shows myofibroblasts 
(aSMA+) leaning on top of adhesive myeloid cells (CD45 +). (c) Collagen deposition in 2D 
microenvironmental co-cultures. Detail d2 shows intracellular retention rather than extracellular 
release of collagen III. Scale bars 100 µm. 
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3.3.3 vi-SNE analysis reveals plasmacytoid and 
activated dendritic cells as main myeloid components in 
human fibroatheroma 
 
To corroborate the ps-plaque model we conducted a comparison study between 
bioengineered and human atherosclerotic plaques isolated from patients that underwent 
carotid endarterectomy. We observed large similarities in population distribution 
within b-plaques and t-plaques. In detail, we found that the main cell populations are 
classical monocytes, macrophages, activated dendritic cells and plasmacytoid dendritic 
cells (Figure 26a, b; Figure 27). When we analyzed CD45+ cells from carotid plaques, 
we identified PDC and aDC populations as main myeloid plaque components (Figure 
26a, b; Figure 28). We further investigated the event density distribution within the 
PDC populations in human carotid plaques. We identified 3 major areas of the vi-SNE 
map corresponding to peculiar PDC phenotypes that we classified as α, β and γ (Figure 
28). PDC type-α represents a relatively small cluster with phagocytic and lipoprotein 
clearance predisposition due to high surface levels of scavenger receptors CD36, SRA-
1 and CD14. PDC type-β is a larger cell cluster characterized by CD16high, indicating 
a possible involvement in pro-inflammatory reactions. PDC type-γ appears to be 
exclusively specialized in lipid and lipoprotein uptake, provided the predominant 
surface expression levels of CD36 (Figure 28). Interestingly, in both bioengineered 
plaque models (b- and t-plaques) we identify PDC Type-β (Figure 27). Finally, we 
analyzed the gene expression profile of the CD45+ populations in ps-plaques and 
carotid plaques. We reported a significant down-regulation of pro-inflammatory and 
remodeling gene targets in carotid plaques compared to bioengineered plaques (Figure 
26c).  
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Figure 26. Comparison between biofabricated plaques and human carotid plaques. (a) vi-SNE maps from CD45+ 
populations isolated from blood-derived plaques (b-plaques), thp1 plaques (t-plaques) and carotid plaques. n=7; 2,000 
events per sample are reported. A total of 14,000 events are shown in each vi-SNE map. (b) The stacked-bar chart 
summarizes the percentage of events for each population. (c) Gene expression profile of CD45+ populations isolated 
from ps-plaques and plaques from carotid arteries. Expression levels of remodeling genes (upper panel) and pro-
inflammatory genes (lower panel). n=5, error bars indicate standard deviation. **p=0.002, ***p<0.001. 
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Figure 27. vi-SNE comparison between bioengineered b-plaques and t-plaques. (a) vi-SNE density 
plots. Areas of high event density are depicted in red and areas with low event density in blue. n=7; 2,000 
events per sample were randomly down-sampled from each sample. A total of 14,000 events is shown in 
each vi-SNE map. (b) Marker expression level plots. 
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3.3.4 Low-density lipoprotein promotes the 
differentiation of a precursor myeloid population in 
biofabricated plaques 
 
We investigated the effects of LDL on the differentiation of myeloid (CD45+) 
subpopulations isolated from b- and t-plaques. To do so, we biofabricated ps-plaques 
using either the established protocol based on LDL-enriched medium or using LDL-
free medium. We applied the vi-SNE workflow to compare the respective cell 
populations. In b-plaques we observed a reduced count of precursors in LDL-enriched 
versus LDL-free controls (p<0.001, Figure 29a, Figure 30) suggesting differentiation 
triggered by LDL. The difference in precursor counts can also be appreciated in the 
respective density plots (Figure 29b, Figure 30). Additionally, we compared vi-SNE 
density plots from ps-plaques biofabricated in LDL-rich and LDL-free medium. To 
investigate variations in LDL triggered surface antigen expression within each 
population we overlapped the density plots with the marker expression level plot. We 
observed an LDL dependent density shift in aDC towards vi-SNE areas with 
CD11chigh, CD16high and CD36high expression levels (Figure 29b, c). In t-plaques, we 
observed an LDL dependent density shift of Mφ1 towards CD36high and CD11chigh 
Figure 28. Density plots from myeloid populations isolated from native carotid plaques. (a) vi-SNE maps indicate 
the event density recorded in each myeloid population. Areas of high event density are depicted in red and areas with 
low event density in blue. PDC sub-populations are indicated in the vi-SNE map: type-α, type-β and type-γ. n=5. 2,000 
events per samples are plotted for a total of 10,000 events. (b) Marker expression level plots. 
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areas of the vi-SNE map and of Mocl towards a CD36high vi-SNE area (Figure 31, 32 
and 33).  
 
 
 
 
Figure 29. LDL effects on myeloid cells isolated from b-plaques. (a) vi-SNE maps indicating myeloid populations 
identified within b-plaques biofabricated either using LDL-enriched (LDL) or LDL-free (w/o LDL) medium. The 
stacked-bar chart summarizes the results from the vi-SNE maps and reports the percentage of events recorded in each 
population. (b) Event density distribution vi-SNE maps show high-density (red) and low-density of events (blue) areas. 
(c) Marker expression level vi-SNE plots. n=7; 2,000 events per sample are reported; 14,000 events are displayed in the 
vi-SNE maps in a and b. vi-SNE maps in c are generated using 2,000 events from all samples. 
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Figure 30. Density plots from CD45+ populations isolated from b-plaques cultured in LDL-enriched (T2L) 
or LDL free (T2) medium. Vi-SNE maps from each biological replicate (a-g) used to assemble the cumulative 
vi-SNE maps and cumulative density maps depicted in Figure 29. 
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Figure 31. LDL effects on t-plaque myeloid populations. vi-SNE maps indicating different 
myeloid populations identified in LDL-rich (LDL) or LDL-free (w/o LDL) t-plaques. The part-
of-whole graph summarizes the results depicted in the vi-SNE maps. n=7; 2,000 events per 
sample are reported for a total of 14,000 events in each vi-SNE map. 
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Figure 32. LDL effects on myeloid populations isolated from t-plaques. (a) Event density maps of 
myeloid populations from LDL-rich (LDL) or LDL-free (w/o LDL) t-plaques.  High-density (red) and low-
density (blue) areas are shown. n=7; 2,000 events per sample are reported. 14,000 events are displayed in 
each vi-SNE map. (b) Marker expression level plots. 
 
 
 79 
 
 
 
 
a
b
c
d
e
f
g
T2 T2L
t-
sn
e	
2	
t-sne	1		
Figure 33. Density plots from CD45+ populations isolated from t-plaques cultured in LDL-enriched (T2L) or 
LDL free (T2) medium. Vi-SNE maps from each biological replicate (a-g) used to assemble the cumulative vi-SNE 
maps and cumulative density maps depicted in Figure 31 and 32. 
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3.3.5 The hanging-drop environment allows the 
establishment of a pro-inflammatory niche 
 
To uncover possible transcriptional effects exerted by LDL on key target genes, we 
investigated the expression profiles of the myeloid component during two steps of the 
ps-plaque biofabrication: (i) after 48h in hanging-drop (T1) and (ii) at the end of the 
hanging-drop process (T2). We compared T1 and T2 from ps-plaques produced in 
LDL-free or LDL-enriched environment. Surprisingly, despite the induction of 
dendritic cell-specific intercellular adhesion molecule DC-SIGN (p<0.001 versus 
p=0.003, Figure 34a) we did not find any significant LDL-dependent transcriptional 
change in b-plaques and t-plaques over time (Figure 34a; Figure 35). On the other hand, 
we found that the hanging-drop process had, per se, a major influence on the gene 
expression levels by directly or indirectly promoting the establishment of a pro-
inflammatory environment. In detail, in b-plaques we observed a significant down-
regulation of CCL26 (p<0.001) and up-regulation of key pro-inflammatory genes 
CXCL10, CCR7 and IL23 (p<0.001) during the transition from T1 to T2 and 
independently from the presence of LDL (Figure 34a). We observed an indirect pro-
inflammatory effect in t-plaques, exerted through the down-regulation of the anti-
inflammatory cytokines CCL26, IL10 and CCL17 (p<0.001, Figure 35). We validated 
these observations performing a control experiment in which we investigated the gene 
expression profile of CD45+ cells using a 2D co-culture approach (Figure 36). As for 
the hanging drop approach, we performed the transcriptomic analysis over time (T1 
and T2) in LDL-free and LDL-enriched medium, using both blood-derived and thp-1 
cells (Figure 36).  When we investigated the transcripts profile of blood-derived cells 
co-cultured in 2D we did not observe any time-dependent pro-inflammatory effect 
apart from the down-regulation of CD26 (p=0.006 in LDL-rich condition; p<0.001 in 
LDL-free condition). When we repeated the experiment using thp-1 co-cultured in 2D, 
not only we did not find any time-dependent pro-inflammatory effect but also, we 
reported a significant time-dependent anti-inflammatory effect achieved with the 
down-regulation of two pro-inflammatory markers: PTGS1 and ALOX5 (both 
p<0.001, Figure 36). 
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Figure 34. Transcript analysis of pro- and anti-inflammatory gene targets in b-plaques and LDL effects on cell 
viability and plaque dimension. (a) Heat-map indicating the expression levels of target genes of interest at T1 and T2 
of b-plaque formation in LDL presence (T1L, T2L) or absence (T1, T2). Expression levels are reported in ΔCt over the 
mean of the housekeeping genes GAPDH and 18S; n=5. (b) ATP levels, indicated in relative luminescence units (RLU), 
were measured and compared in b- and t-plaques; n=5. (c) Plaque circular cross-section area (mm2) as indicator of plaque 
dimension; n=5. (d-e) The ps-plaque necrotic area was measured at the circular cross-section at the great circle of the 
spheroid, and indicated as percentage over alive cells. Living cells (green) are stained with calcein while dead cells (red) 
with Eth-1; n=5, *** p<0.001, scale bar 100µm. 
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Figure 35. Variation in gene expression profiles during t-plaque formation 
Heat-map indicating the expression levels of target genes of interest at T1 and T2 
of t-plaque formation. Ps-plaques were biofabricated either in LDL-rich (T1L, 
T2L) or LDL-free (T1, T2) environment. Expression levels are reported in ΔCt 
over the mean expression of GAPDH and 18S housekeeping genes; n=5. 
 
  
 
 
 
 
 
Figure 36. Expression profile of myeloid cells from 2D microenvironmental co-cultures. Heat maps indicating 
the gene expression level of sorted CD45+ cells during the process of biofabrication (T1 and T2) and treated in 
different conditions (LDL-enriched and free environment). (a) Gene expression data from 2D co-cultures with 
blood-derived cells (n=3). (b) Gene expression data from 2D co-cultures with thp-1 cells (n=3). Expression levels 
are reported in ΔCt over the mean expression of GAPDH and 18S housekeeping genes. 
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3.3.6 Low-density lipoprotein enhances cell death in 
ps-plaques biofabricated with primed blood cells 
 
To further explore the effects of LDL on the ps-plaque model we conducted a bivalent 
analysis. First, we investigated the cell viability within the ps-plaque. We measured 
and compared the ATP levels produced by the biofabricated plaques in LDL-enriched 
and LDL-free medium. We did not find any significant LDL-dependent differences in 
ATP levels in either b- or t-plaques (Figure 34b). However, we observed a general 
tendency of lower ATP levels in plaques produced in LDL-rich environments. We then 
measured the necrotic area at the circular cross-section and we found that b-plaques 
fabricated in presence of LDL had a significantly larger necrotic area in comparison to 
their LDL-free counterparts, suggesting an LDL-dependent necrotic effect (p<0.001, 
Figure 34d, e).  Second, we investigated differences in plaque dimensions to verify 
possible effects of LDL on cell proliferation. We found no difference in circular cross-
section area – consequently in size – of LDL-enriched vs LDL-free plaques (Figure 
34c).  
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3.4 Discussion 
 
With the biofabrication of the ps-plaque we aimed at replicating cellular architecture 
and extracellular microenvironment of a human atherosclerotic plaque to close an open 
modeling gap in the field of atherosclerosis research. It has been described that the 
fibroatheroma cellular composition is mainly characterized by macrophages and 
dendritic cells retaining pro-inflammatory and remodeling abilities [75, 196, 197]. To 
achieve plaque cell populations as similar as possible to human atherosclerotic plaque 
phenotypes we established a differentiation-priming protocol based on a mild LPS 
stimulation of cultured adhesive myeloid cells [198, 199]. To visualize and quantify 
the effects of this procedure on cell population remodeling we used the vi-SNE 
workflow [168, 169, 200]. With this strategy, we identified a total of 15 cell 
populations, differently distributed among samples. We were able to classify these 
populations according to the prevalence of specific surface markers [201, 202]. We 
were also able to track intra-population density shifts and changes in numbers of 
events. The sensitivity of the vi-SNE analysis allowed the identification of under-
represented myeloid populations, otherwise difficult to identify with commonly used 
flow cytometry analysis tools. Thanks to the vi-SNE workflow we identified in blood-
derived myeloid samples both plasmacytoid dendritic cells (PDC) and pre-classical 
dendritic cells (pre-cDCs) [202].  
The vi-SNE analysis reported a yet unidentified myeloid population in both thp-
1 and blood derived samples. We observed a significant decrease of this population 
upon differentiation-priming treatment in both blood-derived and thp-1 samples. The 
decrease was concomitant to a significant increase in pre-cDC count in blood-derived 
samples and to an increase in PDC in thp-1 samples. Based on the current myeloid 
differentiation map [196, 202] and on our observations, we propose that the yet 
unidentified population could be classified as a circulating common precursor of pre-
cDC and PDC, differentiating from the common dendritic cell precursors located in the 
bone marrow (Figure 37). Further investigation on this cell population could improve 
understanding and redesigning of the myeloid differentiation map. 
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Primed cells and myofibroblasts were used for ps-plaque biofabrication and were 
combined to generate a stratified cell-spheroid with myofibroblasts located at the 
periphery and a compact, collagenous and lipid-rich core of CD45+ cells. We sorted 
and compared the CD45+ populations derived from ps-plaques and native human 
carotid plaques using qPCR and the vi-SNE workflow. First, we compared the gene 
expression of CD45+ cells isolated from ps-plaques and native plaques and we reported 
major differences in transcripts level. Second, we investigated and compared the cell 
populations between ps-plaques and native plaques and we found that PDC and 
activated dendritic cells (aDC) are the main myeloid component of thin-cap stage 
atherosclerotic plaques. This finding is per se surprising provided that macrophages 
Figure 37. Proposed hematopoietic differentiation model – the myeloid lineage. In the current model of myeloid 
differentiation, the common macrophage-dendritic cell precursor (MDP) derives from the common myeloid 
progenitor (MP) and gives rise to monocytes and to the common dendritic cell progenitor (CDP). The latter, 
differentiates in plasmacytoid dendritic cells (PDC) and pre-classical dendritic cells (pre-cDC). Pre-cDC, PDC and 
monocytes circulate in the blood and can migrate within the plaque where they differentiate in classical dendritic 
cells (cDC), tissue resident plasmacytoid dendritic cells (PDC), macrophages or monocyte-derived dendritic cells 
(M-DC). In the proposed model a dendritic progenitor can circulate in the blood and differentiate in pre-cDC and 
PDC. 
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and macrophage-derived foam cells are thought to be the main cellular component of 
atherosclerotic lesions, at least in early developmental stages, as discussed by Moore 
and Randolph [203, 204]. Importantly, both PDC and aDC are present in the 
biofabricated models although in low percentages. It is possible that the differences 
found in both gene expression and cell composition when comparing ps-plaques and 
carotid plaques are due to differences in the temporal and developmental stages of both 
plaque types. 
Bonanno et al. previously analyzed the cell component of human carotid 
plaques using flow cytometry showing that about 17% of the lesion (considering cells 
of lymphoid and myeloid origin and smooth muscle cells) is constituted by CD68+ 
cells [205]. They also reported that about 40% of the cells within the plaque expressed 
MHC class II molecules (HLA-DR+) suggesting that these populations could act as 
antigen-presenting cells [205]. It was also proven that early-committed immature DCs 
are positive for CD68 and HLA-DR markers [206], supporting the idea that the cells 
analyzed by Bonanno et al. might have been in part PDC and activated dendritic cells. 
Additionally, it is known that PDC aggravate atherosclerotic lesion formation and that 
their depletion reduces aortic plaque growth by 46% in Apoe-/- mice [207, 208]. PDC 
are also able to uptake oxidized LDL (ox-LDL) ex vivo, and promote PDC-driven 
antigen-specific T-cell proliferation [207]. Finally, it was reported that PDC function 
and cytokine release is impaired in patients suffering from coronary artery disease [209, 
210]. Taken together, these discoveries are in line with our findings and might change 
the scenario of future atherosclerosis treatments. 
 Within the PDC population we identified 3 overrepresented sub-populations 
that we named type-α, type- β and type-γ. We observed that these subpopulations retain 
some degree of specialization due to differential marker expression levels. This 
difference could be the basis of a differential contribution to plaque maturation. For 
instance, PDC type-α display surface marker expression levels (CD36high, CD14high 
and SRA-1high) of a specialized scavenger population [211]. With the ps-plaque model 
we were able to investigate LDL effects on intra-plaque population remodeling and 
cell viability. In detail, we monitored LDL-dependent event density shift within the 
PDC population towards PDC type-β phenotype. This shift was not concomitant with 
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the increase in the PDC count implying a PDC polarization towards CD36high and 
CD16high vi-SNE regions and indicating a possible LDL-triggered acquisition from 
PDC of scavenger and pro-inflammatory phenotype. Additionally, we found that LDL 
presence during ps-plaque formation significantly decreased the count of dendritic 
precursors in both b- and t- plaques and triggered the polarization of aDCs towards 
CD11chigh, CD16high and CD36high levels. These findings are supported by the 
previous observations that LDL and mildly oxidized LDL affect DC maturation and 
promote pro-inflammatory function [212-214]. 
We observed an LDL-dependent decrease of plaque cell viability in b-plaques 
but not in t-plaques. It was shown that LDL and ox-LDL accumulate in the cytoplasm 
of the phagocyte and ultimately contribute to a deregulation of lipid metabolism by 
activating the unfolded protein response (UPR), leading to cell death [215]. The non-
significant decrease in cell viability observed in t-plaques might be due to intrinsic 
differences in population counts among ps-plaque types. In fact, t-plaques show higher 
intermediate monocyte counts when compared to b-plaques. Furthermore, b-plaques 
display a larger population of activated dendritic cells compared to t-plaques. In 
summary, t-plaques are constituted by a more immature cellular milieu compared to b-
plaques. For this reason, we hypothesize that populations within t-plaques would 
require more time to develop towards a death-susceptible stage in presence of LDL. 
We investigated time-dependent effects of LDL on the expression profile of 
myeloid cells within the biofabricated plaque. We found no significant difference in 
transcript levels of selected pro-inflammatory and remodeling target genes [216] 
comparing LDL-rich and LDL-free plaques. LDL effects on myeloid cell transcriptome 
were previously investigated by exposing the cells directly in contact with modified 
forms of LDL and not by directly testing native lipoproteins [217, 218]. However, 
native LDL might retain slower time of action at the transcriptomic level compared to 
its modified counterparts, as previously observed [219]. Interestingly, we detected 
time-dependent gene induction leading to pro-inflammatory cell phenotype 
independently from LDL treatment. The latter was either prompted by direct up-
regulation of pro-inflammatory target genes in b-plaques (CXCL10, CCR7, IL23, 
PTGS1) or indirectly triggered by down-regulation of anti-inflammatory genes in t-
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plaques (CCL17, CCL26, IL10). It was recently shown that three-dimensional spheroid 
cultures of adipose-derived mesenchymal stem cells (MSC) enhance protein levels of 
the anti-inflammatory tumor necrosis factor alpha stimulated gene/protein 6 (TGS-6) 
[220]. On the other hand, the study conducted by Bartosh et al. did not include any test 
to verify the possible concomitant release of pro-inflammatory proteins, leaving an 
unanswered question open for further investigations.  
In conclusion, the ps-plaque is assembled with myeloid cell populations that are 
shared with human native plaques. These cells are embedded in a collagenous and 
lipid-rich extracellular matrix surrounded by a fibrotic layer. To our knowledge the ps-
plaque can be considered the in vitro model closer to human fibroatheroma available 
up to date. Importantly, the present model has the major limitation to not consider sex, 
age and genetic predisposition, which, are in fact, key factors influencing plaque 
initiation and development. In addition, the current model is lacking B and T 
lymphocytes that might provide and important contribution in exacerbating 
inflammation at the plaque level. However, the participation of cells from the adaptive 
immune system to plaque development is still under debate. [221, 222]. In terms of 
acellular components, the model is missing calcification deposits, often encountered in 
late-stage plaques. Despite the absence of calcified areas, calcification is per-se not a 
predictor of unstable plaques (vulnerable plaques) that are prone to rupture and to 
initiate ischemic events [223]. The intra-plaque calcification mechanisms are tightly 
regulated by monocyte/macrophages residing within the plaque [224]. In this regard, 
the 3D plaque model could serve as basis for both (i) further investigations aimed at 
uncovering the mechanisms driving calcium deposition within the atheroma and (ii) 
for the biofabrication of more complex and diversified plaque models mimicking 
different stages of atherosclerosis and peculiar plaque composition. 
Despite the ps-plaque model alone cannot address the complexity of the human 
vascular environment in which wall shear stress, circulating innate and adaptive 
immune cells and variations in LDL cholesterol, blood pressure and diabetes, play a 
pivotal role in modulating plaque development, it provides a tool for investigating 
cellular interplay, viability, metabolism and behavior in a confined environment 
sharing anatomopathological features with human native plaques. The miniaturized 
plaque can be integrated in a 96-well or 384-well platform and used for drug design 
 
 
 89 
and screening purposes. Additionally, it can be employed for increasing the basic 
understanding of late-stage atherosclerosis disease phenomena including possible anti-
inflammatory/atheroprotective role of HDL, plaque calcification and rupture or can be 
integrated in more complex bioengineered dynamic systems, improving existing tissue 
engineered vascular atherosclerosis models [6]. Finally, the biofabrication process can 
be applied to blood-derived myeloid cells isolated from patients with different 
causative mutations of familial hypercholesterolemia (FH, life threatening athero-
prone genetic disorder) in order to produce autologous FH-3D models to identify 
mutation-dependent differences in plaque architecture, cellular composition, cell 
metabolism and viability, with the aim of predicting mutation-dependent disease 
prognosis. 
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Chapter 4 
 
 
Conclusions 
 
 
The mechanisms of atherosclerosis are complex, multivariate, and not fully under-
stood. In vivo models have been employed to study the disease development. However, 
the way atherosclerosis manifests within animal models differs from the pathology seen 
in human, mainly in terms of plaque anatomy and blood lipoprotein profiles. It is thus 
necessary to create new models that accurately reflect the pathophysiology of 
atherosclerosis to be either used to understand the underlying mechanisms of plaque 
formation or to be adopted for pre-clinical studies aiming drug design, testing or 
screening.   
For this dissertation, I successfully biofabricated two new in vitro models for 
the investigation of both early and late-stage atherosclerosis. The models are based on 
two different tissue engineering approaches. The early-lesion model consists in a 
vascular construct fabricated using a scaffold-based direct triple co-culture 
bioengineering strategy where endothelial cells and myofibroblasts are seeded onto a 
biodegradable PGA-P4HB scaffolds and maintained in dynamic pulsatile flow. 
Differently, the late-lesion model is based on a two-step scaffold-free static double co-
culture approach, where cells from myeloid origin are first cultured in hanging drop 
and, upon aggregation in spheroid constructs, are coated with a layer of myofibroblasts. 
Both models are generated employing disease relevant human cell types isolated from 
different sources, i.e. umbilical vein and freshly drawn blood, and aim at mimicking as 
close as possible the pathophysiological environment of the disease at the stage of 
interest. For this purpose, they take advantage from a multidisciplinary approach in 
which tissue engineering, fluid dynamics and immunology techniques are orchestrated 
and combined to work in synergy for the design, fabrication and usage of the model.  
For the early-lesion model described in chapter 2, I designed and assembled a 
fluidic chamber for the simultaneous production of 16 vascular constructs. I performed 
a computational fluid dynamics analysis to understand the flow behavior within the 
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chamber and to predict velocity, pressure and shear stress encounter by the scaffolds 
and cells during tissue engineering. With the aim of producing a tool characterized by 
biologically relevant tunable parameters, as shear stress, pressure and velocity, I 
investigated the optimal size of vascular constructs that could fit in such a system. I 
used the model to investigate whether diverse risk environments could influence the 
differentiation of myeloid populations in the sub-endothelial space of the 
bioengineered vessel. Furthermore, I employed the model to verify whether such 
environments could impair the formation of a stable ECM by investigating variations 
in fibronectin tensional states.  
For the late-lesion model I bioengineered a three-dimensional plaque like 
construct (ps-plaque) using a tailored hanging drop protocol. Using vi-SNE based 
multidimensional flow cytometry data analysis I compared the myeloid cell-
populations in ps-plaques to those in plaques isolated from human carotid arteries. I 
observed that plasmacytoid and activated dendritic cells are the main myeloid 
components of human carotid plaques and that both cell types are present in the 
biofabricated model. Additionally, I found that low-density lipoproteins affect cell 
viability and contribute to population polarization in ps-plaques. The late-stage 
atherosclerosis model describes the first human bioengineered in vitro model of late 
atherosclerotic lesion for the investigation of atherosclerosis aetiopathogenesis. 
Therefore, a patent application has been filed to protect this invention by the 
technology transfer department of the University of Zurich (EP Patent filed 23.08.2017, 
EP 17187562.8). Our late-stage atherosclerosis model can potentially facilitate 
prediction of the main triggers of the disease, estimate disease risk level, determine 
suitable treatments and ascertain the efficacy of potential treatment options. 
Additionally, the miniaturized plaque model is suitable for high-throughput analyses: 
the bioengineered plaques are about 250 µm in diameter and can be easily hosted in a 
96 well or 384 well plate setup (Figure 38, Table 6). 
In conclusion, both models support the 3R principle (Reduce, Replace and 
Refine). In fact, such models could potentially reduce and replace many of the 
experiments performed nowadays on animals, allowing to perform experiments based 
on human cells, with higher translational power. Concretely, the following animal 
models could be replaced: WHHL rabbits, NZW rabbits, apoE-knockout mice, 
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C57BL/6 mice, LDLR-KO (hypercholesteremic) mice, Apob100/100 mice, LDL-DKO 
mice, senescent non-human primates and others. Moreover, both early and late-stage 
atherosclerosis models could serve as an empowering tool for current research. The 3D 
TE models can indeed be used for basic understanding of both early and late-stage 
atherosclerosis disease phenomena, including initiation of plaque formation, 
calcification and rupture and can eventually be used in combination to further expand 
the modeling horizons. 
 
 
 
Figure 38. Upscaling pipeline for the 3D ps-plaque model – the creation of a marketable product. 
Thp1 monocytes will be cultured in vitro up to the desired concentration (about 2 mio cells for one 96 well 
plate). The STEP1 (differentiation-priming) will last about 3 days (72h + 1h). At this point the cells will be 
detached and inserted in a robotic system for STEP 2. Hanging drops of 10μl will be generated 
automatically on the lead of a 96 or 384- well plate. The bottom of the 96/384 well plate be automatically 
filled with 100μl 1XPBS to create a humid environment necessary to keep the drop volume constant. The 
plates will be kept at 37°C and 5% CO2 for 48h. At this point myofibroblasts will be added to the forming 
bioengineered spheroids and the plates will be kept at 37 °C and 5% CO2 for additional 48h. After 1 week 
of processing the product will be ready to be delivered to the costumer. 
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Table 6. Use of the biofabricated late-lesion model for drug testing. 
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